BSR guideline on diagnosis and treatment of giant cell arteritis: executive summary

Author name	Affiliation (institution or patient organisation, city, country)	Professional or patient role
Sarah L. Mackie	University of Leeds, Leeds, UK; Leeds Teaching Hospitals NHS Trust, Leeds, UK	Rheumatologist
Christian Dejaco	Hospital of Bruneck, Bruneck, Italy; and Medical University Graz, Graz, Styria, Austria	Rheumatologist
Simone Appenzeller	Rheumatology Unit, Department of Medicine, University of Campinas, Sao Paolo, Brazil	Rheumatologist
Dario Camellino	Division of Rheumatology, La Colletta Hospital, Local Health Trust 3 Genoa, Italy; and Autoimmunology Laboratory, Department of Internal Medicine, University of Genoa, Italy.	Rheumatologist
Christina Duftner	Medical University Innsbruck, Innsbruck, Austria	Rheumatologist
Solange Gonzalez-Chiappe	Hôpital Saint-Louis, University Paris Diderot, Paris, France	Rheumatologist
Alfred Mahr	Hôpital Saint-Louis, University Paris Diderot, Paris, France	Rheumatologist
Chetan Mukhtyar	Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK	Rheumatologist
Gary Reynolds	Newcastle University, Newcastle, UK	Rheumatologist
Alexandre Wagner S. de Souza	UNIFESP-EPM, São Paulo, Brazil	Rheumatologist
Elisabeth Brouwer	University Medical Center Groningen, University of Groningen, Groningen, The Netherlands	Rheumatologist
Marwan Bukhari	University Hospitals of Morecambe Bay NHS Foundation Trust and Manchester University.	Rheumatologist

Frank Buttgereit	Charité University Medicine, Berlin, Germany	Rheumatologist
Dorothy Byrne	PMRGCAuk	Patient
Maria C. Cid	Hospital Clinic de Barcelona, Universitat de Barcelona, Institut d'Investigacions, Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain	Internist
Marco Cimmino	Università degli Studi di Genova, Genoa, Italy	Rheumatologist
Haner Direskeneli	Marmara University, Istanbul, Turkey	Rheumatologist
Kate Gilbert	PMRGCAuk	Patient
Tanaz A. Kermani	UCLA Medical Center, UCLA, Santa Monica, USA	Rheumatologist
Asad Khan	Solihull Hospital, University Hospitals Birmingham, Birmingham, UK	Rheumatologist
Peter Lanyon	Nottingham University Hospitals, UK	Rheumatologist
Raashid Luqmani	University of Oxford, Oxford, UK	Rheumatologist
Christian Mallen	Keele University, Staffordshire, UK	General Practitioner
Justin C. Mason	Imperial College London, London, UK	Rheumatologist
Eric L. Matteson	Mayo Clinic College of Medicine and Science, Rochester, USA	Rheumatologist and epidemiologist
Peter A. Merkel	University of Pennsylvania, Philadelphia, USA	Rheumatologist and epidemiologist
Susan Mollan	University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK	Ophthalmologist
Lorna Neill	PMR-GCA Scotland	Patient
Eoin O'Sullivan	King's College Hospital, London, UK	Ophthalmologist
Maria Sandovici	University Medical Center Groningen, University of Groningen, Groningen, The Netherlands	Rheumatologist

2

Wolfgang A. Schmidt	Immanuel Hospital Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany	Rheumatologist
Richard Watts	Ipswich Hospital, Ipswich, UK, and University of East Anglia, Ipswich, UK	Rheumatologist
Madeline Whitlock	Southend University NHS Foundation Trust	Rheumatology specialist nurse
Elaine Yacyshyn	University of Alberta, Edmonton, Canada	Rheumatologist
Steven Ytterberg	Mayo Clinic of Medicine and Science, Rochester, USA	Rheumatologist
Bhaskar Dasgupta	Southend Univerity Hospital NHS Foundation Trust, Southend, UK	Rheumatologist

Corresponding author:

University of Leeds - Leeds Institute of Rheumatic and Musculoskeletal Medicine

Chapel Allerton Hospital Harrogate Road , Leeds s.l.mackie@leeds.ac.uk

Background and need

Giant cell arteritis (GCA), or temporal arteritis, is a large-vessel vasculitis affecting older people(1). Without high-dose glucocorticoid treatment, GCA can lead to occlusion of cranial blood vessels, which may result in blindness or stroke(2). Most occurrences of blindness or stroke happen either before treatment, or during the first week of treatment(3). GCA is therefore a medical emergency requiring immediate treatment. Many patients with GCA have inflammation of the aorta and its proximal branches (extracranial large-vessel involvement) which can lead to aortic aneurysm, dissection or rupture(4). Recent years have seen new evidence emerge regarding diagnosis and treatment of GCA, requiring a major update of the 2010 British Society for Rheumatology (BSR) guideline(5).

Objectives To provide guidance for clinicians in the diagnosis and treatment of GCA, supported by evidence where possible.

Target audience This guideline is intended for doctors and allied health professionals who work in a primary or secondary care setting and manage patients with suspected and/or established GCA.

Areas not covered Takayasu arteritis(6), isolated polymyalgia rheumatica (PMR)(7, 8), and management of glucocorticoid-related complications such as osteoporosis(9).

For details concerning each section please refer to the full guideline published online.

This guideline was developed using GRADE (Grading of Recommendations, Assessment, Development and Evaluations) to produce evidence-based recommendations(10).

General principles

"General Principles" are not necessarily evidence-based but are a description of generally-accepted best medical practice. Each General Principle carries a consensus score (mean rating on a 0-10 scale). Further practical guidance for clinicians is also provided where relevant.

How should suspected GCA be treated?

1. Patients in whom GCA is strongly suspected should be immediately treated with high-dose glucocorticoids. Consensus score: 9.61

"Strongly suspected" GCA means that in the assessing clinician's judgement, GCA is a more likely explanation for the patient's symptoms than any other condition. For doses, see *Treatment of GCA*, below.

How quickly should patients with suspected GCA be referred for evaluation?

2. GCA is a medical emergency. Each local healthcare organisation should have information available to front-line clinicians, such as general practitioners and clinicians working in acute care, on how to refer patients with suspected GCA urgently for local specialist evaluation: patients should be evaluated by a

specialist ideally on the same working day if possible and in all cases within 3 working days. Consensus score: 9.17.

GCA is a medical emergency and therefore "fast-track" referral pathways for urgent specialist evaluation of suspected GCA are beneficial. On suspicion of GCA, primary care providers should initiate glucocorticoids alongside an urgent referral to the local GCA pathway.

To whom should patients with suspected GCA be referred?

3. Patients with suspected GCA should be evaluated by a clinician with appropriate specialist expertise, usually a rheumatologist. Patients presenting with a history of new visual loss (transient or permanent) or double vision should be evaluated as soon as possible on the same calendar day by an ophthalmologist. Consensus score: 9.61.

What evaluations should be performed when starting treatment?

4. When starting glucocorticoids for suspected GCA, diagnostically relevant symptoms and signs should be documented. Blood should be taken for full blood count, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) before or immediately after commencing high-dose glucocorticoids. If GCA is strongly suspected, the first dose of glucocorticoid can be given without waiting for laboratory results. Consensus score: 9.61

Diagnostically relevant symptoms and signs of GCA include headache; scalp hyperaesthesia; jaw or tongue claudication; temporal artery tenderness, nodularity or reduced pulsation; visual manifestations including diplopia or changes to colour vision; limb claudication; polymyalgia rheumatica (pain and stiffness of shoulder and hip girdles); fevers, sweats or weight loss. Less commonly, patients may have carotidynia, audiovestibular symptoms, dry cough, or indications of tongue or scalp ischaemia that may precede necrosis. However, as none of these symptoms are entirely specific for GCA, each is of limited use if taken in isolation(11) and differential diagnosis must also be considered. GCA causes elevation in platelet count, CRP and ESR. Plasma viscosity can be used where ESR is unavailable. These markers all fall with glucocorticoid therapy; therefore, all patients should have blood drawn prior to starting treatment, unless there is evidence of critical ischaemia such as visual loss or diplopia and no immediate access to phlebotomy.

What evaluations should be performed soon after starting treatment for GCA?

5. Patients treated for GCA should be evaluated for features of the disease
relevant to prognosis, such as clinical and laboratory features of a marked
inflammatory response at diagnosis, ischaemic manifestations such as
transient visual loss or jaw/tongue claudication, and signs or symptoms
indicating involvement of the aorta and its proximal branches; and for co-
morbidities relevant to treatment, such as diabetes mellitus, hypertension, and
bone fracture risk. Consensus score: 9.53

Table 1 summarises recommended assessments for patients with GCA. As well as
confirmatory tests for GCA (see Key Recommendation 1), alternative explanations for
patients' symptoms should be considered, particularly if these confirmatory tests are
negative.

It is best practice for the prescriber of glucocorticoid therapy to ensure that patients are
evaluated for hypertension and hyperglycaemia (blood glucose for acute changes and/or
HbA1c to identify patients that might be at greater risk) within the first 2 weeks of
commencing high-dose glucocorticoids. Patients receiving high-dose glucocorticoids are
at elevated risk of osteoporosis and bone fracture; this risk should be managed
appropriately.

In GCA, involvement of the aorta and its proximal branches is often asymptomatic but
may cause vascular bruits or reduced blood pressure in one or both arms. Clinicians
should be aware of an increased risk of thoracic aortic aneurysm and dilatation; this may
occur at any time during the disease course(4). However, routine aortic imaging for all
GCA patients remains of uncertain cost-effectiveness. The optimal method and timing of
imaging is still unclear(12). Therefore clinicians are advised to use their own discretion
regarding selection of patients for aortic imaging.

Table 1. A proposed list of clinical assessments that could be carried out at or near diagnosis
of giant cell arteritis (GCA).

6

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

History and examination	Investigations
• Height and weight • Features of GCA relevant to prognosis: fever, sweats, or weight loss; ischaemic manifestations (jaw claudication, tongue claudication) • Signs and symptoms indicating involvement of extracranial arteries e.g. bruits, different blood pressures in the two arms, limb claudication • Ophthalmological evaluation for patients with transient or permanent visual loss or diplopia • History of comorbidities and medications that might predispose to glucocorticoid-related adverse effects: infection, hypertension, diabetes, osteoporosis, low-trauma fracture, dyslipidaemia, peptic ulcer, psychiatric adverse effects • Features that may suggest alternative diagnosis, e.g. neurological deficits, very severe constitutional symptoms, or localised ear, nose and throat signs	• Measures of activity of GCA: laboratory markers of inflammation (CRP for all patients, plus either ESR or plasma viscosity), and full blood count (platelet count may be elevated in GCA). • Consider serum protein electrophoresis and urine Bence-Jones protein/serum free light chains if ESR raised out of proportion to CRP • Baseline laboratory tests of major organ system function (plasma glucose, renal and liver function tests, calcium and alkaline phosphatase) • Screening tests for risk of serious infection* (may include urine dipstick, chest radiograph, tests for latent tuberculosis according to local or national protocol) • Screening tests for osteoporosis risk* (may include TSH, vitamin D, bone density test (DXA))

Legend for Table 1:

*Screening tests for infection and osteoporosis to be considered in light of relevant local and national guidelines. Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; TSH, thyroid stimulating hormone; DXA, dual-energy x-ray absorptiometry.

How should ongoing management of GCA be individualised?

6. Full assessment of the disease and co-morbidities, and consideration of the patient's personal priorities, should inform decisions about glucocorticoid tapering and initiation of additional treatments such as glucocorticoid-sparing therapies. Involvement of, and clear communication with, primary care physicians is critical especially for management of multimorbidity. Consensus score: 9.67

Table 2 shows an example of glucocorticoid tapering for GCA.

Table 2. An example of glucocorticoid tapering for giant cell arteritis.

This is an example of glucocorticoid tapering based on that described in the 2010 BSR guidelines for GCA(5) and similar to the control arm of a recent clinical trial(13). High-quality evidence comparing different glucocorticoid taper schedules in GCA is not available. Alternative approaches include, for example, reducing prednisolone by 10mg/week in patients who are in remission above 20mg daily, and/or reducing the dose slower than stated here in patients who are on or below 5mg daily. In all cases taper schedules should be individualised based on the patient. For relapse management, see Table 3.

Daily prednisolone dose	Example rate of reduction in daily prednisolone dose	Notes
40-60mg oral prednisolone: initial dose for patients with active GCA	Continue at same dose until GCA symptoms and acute phase markers resolve	Purpose: induction of clinical remission

1

In clinical remission, and above 20mg prednisolone	Reduce daily dose by 10mg every 2 weeks	Aim to reach 20mg prednisolone once the patient has been in remission for 4-8 weeks.

If symptoms suggestive of GCA relapse occur during taper, consult Table 3 |
| In clinical remission, above 10mg prednisolone but less than 20mg | Reduce daily dose by 2.5mg every 2-4 weeks | |
| In clinical remission, and on 10mg prednisolone or less | Reduce daily dose by 1mg every 1-2 months | |

What education should patients be offered?

7. All patients with GCA should be provided with information about GCA and

its treatment. Patients should receive advice on diet, physical activity and stopping smoking. Consensus score: 9.47.

Information should be available at least in written format and ideally in multiple formats. Dietary considerations include mitigating the potential effects of glucocorticoid therapy on body weight, post-prandial glycaemia and bone fracture risk. Recommendations on physical activity in inflammatory arthritis and osteoarthritis(14) may be tailored to individual patients with GCA. Patients should be signposted to relevant patient support groups or charities as sources of peer support. Patients should be advised of potential symptoms of glucocorticoid withdrawal, although these are uncommon in practice. Patients should be advised about alteration of glucocorticoid dose in intercurrent illness, especially including advice for seeking emergency attention if they suffer a vomiting illness necessitating parenteral glucocorticoid.

What plans should be made for possible future GCA relapses?

8. During glucocorticoid taper and after glucocorticoid cessation, patients should be informed what symptoms may suggest GCA relapse and what action the patient should take in these circumstances, including first point of contact for medical advice and how to contact the team providing specialist care.

Consensus score: 9.81

Table 3 shows examples of symptoms that may signify relapse in patients with GCA, and how they might be managed.

Table 3. Examples of symptoms that may signify relapse of GCA during glucocorticoid taper that require further evaluation and, if judged to be due to GCA relapse, escalation of glucocorticoid treatment.

This table outlines how new symptoms in GCA patients, in the absence of other risk factors or significant co-morbidities, may influence management decisions. New visual loss or diplopia should be urgently evaluated by an ophthalmologist. Acute phase markers should be measured and, if found to be elevated, may increase the clinical suspicion of GCA relapse. At present, the only agents with any evidence for glucocorticoid-sparing in GCA are methotrexate and tocilizumab.

Symptom	Possible significance in a patient with GCA	Action to consider if symptom is judged to be due to GCA relapse
Return of headache symptoms	Possible GCA relapse without ischaemic manifestations	Return to previous higher prednisolone dose
Jaw or tongue claudication	Possible GCA relapse with ischaemic manifestations	Consider high-dose oral prednisolone (40-60mg) with or without glucocorticoid-sparing agent

1

Weight loss, fever, night sweats, anaemia, persistent acute phase response, new/recurrent PMR symptoms, limb claudication, abdominal pain or back pain	Possible GCA-related inflammation of the aorta and/or its proximal branches	Investigate with vascular imaging (MRI, CT or FDG-PET/CT); consider increasing oral prednisolone and/or adding glucocorticoid-sparing agent

Key recommendations

The following evidence-based recommendations are graded as strong or conditional, with the quality of the evidence given as ++++ to + (unless no evidence was found) and a consensus

score to indicate mean strength of agreement. Further essential elaboration is added below where necessary. The underlying evidence and additional explanatory notes are presented in

more detail in the full guideline document.

Diagnostic tests for GCA

Which additional confirmatory diagnostic tests should be performed in all patients with

suspected GCA? (PICO 1, 2)

1. Strong recommendation: Patients with suspected GCA should have a confirmatory

   diagnostic test. This could be either a temporal artery biopsy at least 1cm in

   length, or an ultrasound of the temporal and axillary arteries, or both. QoE: +++
   Consensus score: 9.33.

In selecting and interpreting the results of confirmatory diagnostic tests, pre-test probability (established on clinical grounds) should be taken into account(15) (Figure 1). A positive

temporal artery biopsy, showing features of inflammation characteristic of GCA such as giant

cells or panarteritis(16), confirms the diagnosis of GCA. Isolated vasa vasorum vasculitis is not diagnostic of GCA. Due to the possibility of skip lesions, the length of biopsy should be

at least 1cm (post-fixation). Ultrasound is operator-dependent and requires adequate training, but has the advantage of access to both superficial temporal arteries in their entirety(15).

Where temporal artery histology findings are ambiguous (e.g. low-level inflammation

restricted to the adventitia), discussion between the requesting clinician and the pathologist is

1

desirable. In the absence of inflammatory infiltrate, a report of healed arteritis is not sufficient

to diagnose GCA. If neither vascular ultrasound nor biopsy is possible, and local MRI

facilities and radiology support are available, then high-resolution 3 Tesla MRI of the cranial

arteries could be used instead(15).

Which tests can be used to evaluate involvement of the aorta and its proximal branches in GCA? (PICO 2, 3)

2. Conditional recommendation: 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), magnetic resonance angiography (MRA), computed tomography angiography (CTA) or axillary artery ultrasound may be used to evaluate involvement of the aorta and its proximal branches. QoE: + Consensus score: 9.36.

Since involvement of the aorta and its proximal branches in GCA may be asymptomatic or

associated only with constitutional symptoms, in some circumstances directed vascular imaging of the aorta and its proximal branches can be useful to detect inflammation, stenosis

or dilatation. FDG-PET can be useful for assessment of vascular inflammation although it provides less detailed anatomic definition of the involved arteries compared to MRA or CTA. Imaging may also be useful for follow-up assessments. Additional advantages of FDG-PET

and CT include potential value in the workup of alternative diagnoses such as malignancy and infection. Ultrasound can assess the axillary arteries but ultrasound evaluation of the deeper

arteries is more difficult.

Treatment of GCA

What is the best dose and route of initial glucocorticoid therapy for GCA in the absence of ischaemic visual manifestations? (PICO 1-3)

3. Conditional recommendation: The standard initial glucocorticoid dose for GCA is 40-60mg oral prednis(ol)one per day. QoE: + Consensus score: 9.44.

The vast majority of patients with GCA respond symptomatically within 1-7 days to a 40-

60mg daily dose of prednis(ol)one, apart from irreversible sequelae such as established visual

loss, stroke or tissue necrosis. Failure to respond to this dose should prompt re-evaluation of

the diagnosis.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

What is the best dose and route of initial glucocorticoid therapy for GCA in the presence of ischaemic visual manifestations? (PICO 4)

4. Conditional recommendation: GCA patients with acute or intermittent visual loss may initially be given 500mg – 1g intravenous methylprednisolone daily for up to 3 consecutive days before commencing oral prednis(ol)one therapy. If intravenous therapy is not immediately possible, this should not delay initiation of oral prednis(ol)one. QoE: + Consensus score: 9.00.

Acute visual loss due to ocular ischaemia in GCA requires immediate action. If intravenous glucocorticoid therapy is not possible, 60-100mg oral prednisolone may be given for up to 3 consecutive days. Clinical trials have not been conducted in patients with acute ocular ischaemia, but observational data indicates that the vast majority of visual loss in GCA occurs before initiation of glucocorticoid therapy(3).

How should glucocorticoid dose be tapered in GCA? (PICO 5)

5. Conditional recommendation: Glucocorticoid dose should be tapered to zero over 12-18 months, providing there is no return of GCA symptoms, signs or laboratory markers of inflammation. A more rapid dose reduction is appropriate for patients at high risk of glucocorticoid toxicity and/or those receiving concomitant glucocorticoid-sparing therapy. QoE: + Consensus score: 8.81.

All taper schedules assume close and regular clinical follow-up and good communication between patients and care provider should symptoms change (see Tables 2 and 3).

What dosing frequency of oral glucocorticoid should be used in GCA? (PICO 6, 7)

6. Conditional recommendation: Patients should be prescribed a single daily dose of glucocorticoid, rather than alternate day dosing or divided daily dosing. QoE: + Consensus score: 9.53.

Should modified release prednisone be used in place of standard therapy? (PICO 8)

1

7. No recommendation can be made for the use of modified release prednisone in the treatment of GCA. QoE: insufficient evidence. Consensus score: 9.72.

When should further, non-biologic immunosuppression be added to glucocorticoid therapy for GCA? (PICO 9,10)

8. Conditional recommendation: Methotrexate might be considered for GCA, in combination with a glucocorticoid taper, in patients at high risk of glucocorticoid toxicity or who relapse. There is insufficient evidence to recommend any other oral immunosuppressive agent in GCA, including azathioprine, leflunomide or mycophenolate mofetil. QoE: ++ Consensus score: 8.92.

Methotrexate, which may be given orally or by subcutaneous injection, has been used at doses of 7.5-15mg weekly in clinical studies and up to 25mg weekly in clinical practice. On the basis of three randomised controlled trials, conducted in patients with recent-onset GCA, the evidence for methotrexate as a glucocorticoid-sparing agent in GCA remains equivocal, acknowledging limitations of the evidence base. In contrast, other immunosuppressants (including azathioprine, leflunomide, mycophenolate) have not been adequately tested in clinical trials. The potential toxicity of dapsone or ciclosporin is likely to outweigh any possible benefit and their use is not recommended.

Which biologic agents can be used for GCA in addition to standard therapy? (PICO 11, 12)

9. Strong recommendation: Tocilizumab can be considered for GCA, in combination with a glucocorticoid taper, especially in patients at high risk of glucocorticoid toxicity or who relapse. TNF inhibitors are not recommended in GCA. QoE: +++ Consensus score: 9.61.

Tocilizumab was approved for GCA by the US and European regulatory authorities in 2017 on the basis of two randomised clinical trials (13, 17) of one year of tocilizumab versus placebo, alongside tapering oral glucocorticoid therapy, demonstrating efficacy for tocilizumab in GCA.

Although efficacy was demonstrated both in new-onset and relapsing GCA, the cost-effectiveness of a glucocorticoid-sparing therapy in GCA is likely to be better in those with relapsing GCA, or in those GCA patients for whom the dose required to control disease activity exceeds the maximum glucocorticoid dose acceptable for that individual, for example

due to co-morbidities such as neuropsychiatric glucocorticoid-related adverse effects,

previous fragility fractures, or difficult-to-control diabetes mellitus.

UK prescribers should be aware that at the time of writing a limited duration of tocilizumab therapy for GCA has been approved by the Scottish Medicines Consortium and by NHS

England for defined patient groups, taking into account cost-effectiveness data available at the time of the technology appraisal by NICE (TA518).

Clinical trials of TNF inhibitors have failed to demonstrate efficacy in GCA. One small trial

of abatacept for GCA has been reported(18), but so far there is insufficient evidence to make a treatment recommendation for this agent.

Should anticoagulant or antiplatelet agents be given for GCA? (PICO 12-15)

10. The routine use of antiplatelet or anticoagulant agents for GCA is not recommended. QoE: insufficient evidence. Consensus score: 9.28

There is a lack of evidence for the use of antiplatelet or anticoagulant agents specifically for GCA. National and society guidelines for the secondary prevention of coronary and other atherosclerotic vascular diseases should be followed.

Should cholesterol-lowering agents be given for GCA? (PICO 16)

11. The routine use of cholesterol-lowering agents such as statins for GCA is not recommended. QoE: insufficient evidence. Consensus score: 9.53

There is a lack of evidence for the use of cholesterol-lowering agents specifically for GCA. National and society guidelines for the secondary prevention of coronary and other atherosclerotic vascular diseases should be followed.

1

Figure 1. A possible approach to using rapid-access vascular ultrasound to assist in clinical

diagnostic decision-making in suspected cranial GCA.

This figure illustrates a possible approach to using rapid-access vascular ultrasound, if

available, in suspected GCA. Estimation of probability of GCA is based on all information

available (symptoms, signs, laboratory tests, and alternative non-GCA explanations for the
clinical picture) and can be updated based on new information (clinical course, result of

temporal and axillary ultrasound and/or result of temporal artery biopsy). This assessment is
based on clinical judgement and should ideally be performed by an individual with specialist

expertise. Note that for a medium (20-50%) estimated probability of GCA, it may be useful to

perform an ultrasound prior to biopsy, in case the biopsy is negative. For a high clinical

probability of GCA, a positive ultrasound alone may be sufficient, as illustrated here;

however, in these cases it is still acceptable to perform biopsy in addition to ultrasound in
order to further increase diagnostic certainty. In the absence of clinical features of cranial

GCA, temporal artery biopsy can still be positive, but imaging of the extracranial large

vessels may be considered instead of, or in addition to, temporal artery biopsy. Recently

various clinical prediction rules have been proposed to assist clinicians in the estimation of

probability of GCA; the performance of a clinical prediction rule developed in another setting should ideally be checked using local audit data prior to adopting into local clinical practice. If rapid-access vascular ultrasound is not available, patients treated for suspected GCA should all have a temporal artery biopsy. None of these tests should delay the prescribing of high-dose glucocorticoid therapy for patients with strongly-suspected GCA.

Susan Mollan - Roche (Advisory boards 2016, 2017) Roche speaker fees (2016, 2017, 2018, 2019) Chugai-Roche Ltd speaker fees (2018, 2019).

Dario Camellino - Travel expenses, consultancy and speaker fees from AbbVie, Celgene, Janssen-Cilag, Lilly, Mylan, Sanofi. None of them was related to this project.

Bhaskar Dasgupta - Paid consultancies for membership of Clinical Trials Advisory Boards, for developing trials protocols as well as speaker fees from Roche-Chugai, Sanofi, ERT, BMS, GSK,Abbvie as well as Ultrasound workshop/GCA symposium grants to Southend university Hospital.

Marwan Bukhari - I have been involved in the GCA consortium, which is indirectly funded by Roche/ chugai. I have also been involved in a virtual advisory board by Roche pharmaceuticals about managing GCA.

Disclosures:

Sarah Mackie - I am Patron of PMRGCAuk which is a patient support group (not to my knowledge in receipt of funding from industry) that also undertakes advocacy.   I am employed by the University of Leeds as an academic rheumatologist and as required for my role I have published various academic publications on GCA. I am also a founder member of the TARGET Research Consortium https://lida.leeds.ac.uk/target-2/about-us/ which is a partnership between academics, industry and clinicians.   I am co-chair of the OMERACT PMR Working Group and a member of the OMERACT Vasculitis Working Group which includes large vessel vasculitis as part of its remit.   I am also encouraged to carry out public engagement roles and I speak sometimes to patient support groups. I was interviewed by a journalist on behalf of a US patient support group called creakyjoints.org and was quoted in the online article but I avoided being quoted on any specific therapy https://creakyjoints.org/education/giant-cell-arteritis/   I was sub-investigator at my hospital for the licensing RCT of tocilizumab for giant cell arteritis (GiACTA), site PI and for sirukumab for giant cell arteritis (SIRRESTA) I am local principal investigator and UK CI (for purposes of IRAS) for an international multicentre industry sponsored trial of sarilumab for GCA.

Asad Khan - I have co-authored a review entitled "Imaging in Giant Cell Arteritis" (DOI 10.1007/s11926-015-0527-y). This review is related to the likely contents of the guideline but did not form part of the evidence base for it.

Christian Dejaco - First author of EULAR imaging recommendations in large vessel

vasculitils First author of ACR/EULAR recommendations for management of PMR

Coauthor of management recommendations for Large vessel vasculitis.

Lorna Murray Neill - Current Chair of PMR-GCA Scotland.

Peter A. Merkel - Research Support: Bristol-Myers Squibb, Genentech/Roche.

Maria Cid - In the last year I have participated in clinical trials sponsored by GSK, and

Kiniksa   I have participated as co-author in publications of work sponsored by Roche.

Kate Gilbert - I am a representative of PMRGCAuk, the national charity for patients with

polymyalgia rheumatica and giant cell arteritis, and my involvement with this guideline

enhances the public profile of the charity.

Dorothy Byrne - Vice Chair of PMRGCAuk.

Elisabeth Brouwer - Presently I perform cohort research in GCA as an employee of the

UMCG in the Netherlands. Part of the work is funded by Reuma Nederland. I also lead/ am

involved in the development of the local and national guidelines for GCA in the

Netherlands..

Elaine A. Yacyshyn - Associate Professor Rheumatology at University of Alberta i) I have

been asked to speak at an educational event sponsored by a pharmaceutical company which is

related to my area of expertise. Action: Wrote my own slides, did not accept financial

payment which went to Institution.

Wolfgang Andreas Schmidt - Participation in trials / studies: GlaxoSmithKline, Novartis,

Roche, Sanofi.

Eric Matteson - Task force participation: EULAR 2018 standardized core set of data to be

collected in giant cell arteritis registries and databases.

Justin Mason - I am Professor of Rheumatology at Imperial College London and Head of the

Cardiovascular Division.

Susan P Mollan - I was the representative from the Royal College of Ophthalmologists for

this guideline. I was part of the EULAR GCA guideline group. I am part of the European

Headache Federation GCA guideline group.   I was author of the Cochrane review in

recommending utility of Aspirin in GCA.

Lorna Neill - Chair of PMR-GCA Scotland Patient representative on EULAR working group on Imaging in LVV.

Bhaskar Dasgupta - I am the Honorary President of PMRGCAuk , a patient support charity I was investigator for GiACTA, co-author of the NEJM article that led to approval of tocilizumab for GCA, and led the BSR response to NICE that facilitated NICE approval of tocilizumab for relapsing/refractory GCA I was the subject of the BBC2 Health program 'Trust me, I'm a doctor' made on GCA and released Feb 2017 I have authored over 200 artcles on GCA,PMR and was the first author of the original BSR guidance on GCA as well PMR (including the EULAR ACR guidance on PMR).

Peter Lanyon - I was President of the BSR April 2016-18. I currently chair the Rare Autoimmune Rheumatic Disease Alliance.

Key References

1.   Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990-2001. Annals of the rheumatic diseases. 2006;65(8):1093-8.

2.   Weyand CM, Goronzy JJ. Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. The New England journal of medicine. 2014;371(1):50-7.

3.   Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, Martinez-Taboada VM, Delgado-Rodriguez M, Figueroa M, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998;41(8):1497-504.

4.   Garcia-Martinez A, Arguis P, Prieto-Gonzalez S, Espigol-Frigole G, Alba MA, Butjosa M, et al. Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation). Ann Rheum Dis. 2014;73(10):1826-32.

5.   Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):1594-7.

6.   Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68(3):318-23.

7.   Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015;74(10):1799-807.

8.   Dasgupta B, Borg FA, Hassan N, Barraclough K, Bourke B, Fulcher J, et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford). 2010;49(1):186-90.

9.   Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017;69(8):1521-37.

10.   Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-6.

11.   Smetana GW, Shmerling RH. Does this patient have temporal arteritis? Jama. 2002;287(1):92-101.

12.   Mackie SL, Hensor EM, Morgan AW, Pease CT. Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis. Annals of the rheumatic diseases. 2014;73(1):143-8.

13.   Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of Tocilizumab in Giant-Cell Arteritis. The New England journal of medicine. 2017;377(4):317-28.

14.   Rausch Osthoff AK, Niedermann K, Braun J, Adams J, Brodin N, Dagfinrud H, et al. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Annals of the rheumatic diseases. 2018;77(9):1251-60.

15.   Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Annals of the rheumatic diseases. 2018;77(5):636-43.

16.   Lie JT. Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis. Arthritis and rheumatism. 1990;33(8):1074-87.

17.   Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2016;387(10031):1921-7.

18.   Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, et al. A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. Arthritis & rheumatology (Hoboken, NJ). 2017;69(4):837-45.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

BSR guideline on diagnosis and treatment of giant cell arteritis: full guideline to be published electronically.

Author name	Affiliation (institution or patient organisation, city, country)	Professional or patient role
Sarah L. Mackie	University of Leeds, Leeds, UK; Leeds Teaching Hospitals NHS Trust, Leeds, UK	Rheumatologist
Christian Dejaco	Hospital of Bruneck, Bruneck, Italy; and Medical University Graz, Graz, Styria, Austria	Rheumatologist
Simone Appenzeller	Rheumatology Unit, Department of Medicine, University of Campinas, Sao Paolo, Brazil	Rheumatologist
Dario Camellino	Division of Rheumatology, La Colletta Hospital, Local Health Trust 3 Genoa, Italy; and Autoimmunology Laboratory, Department of Internal Medicine, University of Genoa, Italy.	Rheumatologist
Christina Duftner	Medical University Innsbruck, Innsbruck, Austria	Rheumatologist
Solange Gonzalez-Chiappe	Hôpital Saint-Louis, University Paris Diderot, Paris, France	
Alfred Mahr	Hôpital Saint-Louis, University Paris Diderot, Paris, France	Rheumatologist
Chetan Mukhtyar	Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK	Rheumatologist
		Rheumatologist
Gary Reynolds	Newcastle University, Newcastle, UK	Rheumatologist
Alexandre Wagner S. de Souza	UNIFESP-EPM, São Paulo, Brazil	Rheumatologist
Elisabeth Brouwer	University Medical Center Groningen, University of Groningen, Groningen, The Netherlands	Rheumatologist
Marwan Bukhari	University Hospitals of Morecambe Bay NHS Foundation Trust and Manchester University.	Rheumatologist
Frank Buttgereit	Charité University Medicine, Berlin, Germany	Rheumatologist
Dorothy Byrne	PMRGCAuk	Patient
Maria C. Cid	Hospital Clinic de Barcelona, Universitat de Barcelona, Institut d'Investigacions, Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain	Internist
Marco Cimmino	Università degli Studi di Genova, Genoa, Italy	Rheumatologist
Haner Direskeneli	Marmara University, Istanbul, Turkey	Rheumatologist
Kate Gilbert	PMRGCAuk	Patient
Tanaz A. Kermani	UCLA Medical Center, UCLA, Santa Monica, USA	Rheumatologist
Asad Khan	Solihull Hospital, University Hospitals Birmingham, Birmingham, UK	Rheumatologist
Peter Lanyon	Nottingham University Hospitals, UK	Rheumatologist
Raashid Luqmani	University of Oxford, Oxford, UK	Rheumatologist

36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Christian Mallen	Keele University, Staffordshire, UK	General Practitioner
Justin C. Mason	Imperial College London, London, UK	Rheumatologist
Eric L. Matteson	Mayo Clinic College of Medicine and Science, Rochester, USA	Rheumatologist and epidemiologist
Peter A. Merkel	University of Pennsylvania, Philadelphia, USA	Rheumatologist and epidemiologist
Susan Mollan	University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK	Ophthalmologist
Lorna Neill	PMR-GCA Scotland	Patient
Eoin O'Sullivan	King's College Hospital, London, UK	Ophthalmologist
Maria Sandovici	University Medical Center Groningen, University of Groningen, Groningen, The Netherlands	Rheumatologist
Wolfgang A. Schmidt	Immanuel Hospital Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany	Rheumatologist
Richard Watts	Ipswich Hospital, Ipswich, UK, and University of East Anglia, Ipswich, UK	Rheumatologist
Madeline Whitlock	Southend University NHS Foundation Trust	Rheumatology specialist nurse
Elaine Yacyshyn	University of Alberta, Edmonton, Canada	Rheumatologist
Steven Ytterberg	Mayo Clinic of Medicine and Science, Rochester, USA	Rheumatologist
Bhaskar Dasgupta	Southend Univerity Hospital NHS Foundation Trust, Southend, UK	Rheumatologist

Corresponding author:
University of Leeds - Leeds Institute of Rheumatic and Musculoskeletal Medicine
Chapel Allerton Hospital Harrogate Road , Leeds s.l.mackie@leeds.ac.uk

This guideline was developed in accordance with the BSR's Guidelines Protocol.

Scope and Purpose

1. Background to disease

GCA is a large-vessel vasculitis affecting older people, with highest incidence among persons 70-79 years of age(1). Due to forecasted demographic changes, it has been estimated that between 2014 and 2050, more than 3 million people will have been diagnosed with GCA in Europe, North America and Oceania(2).

In GCA there is inflammation within the walls of medium and large-sized arteries, with associated intimal hyperplasia(3). The ischemia to end organs results in characteristic

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

clinical features such as jaw or limb claudication(4). Visual loss or stroke may occur in GCA, attributed to vascular occlusion; most GCA-associated visual loss occurs prior to glucocorticoid treatment or shortly after treatment initiation, underlining the importance of immediate treatment if the disease is strongly suspected(5, 6). The reported proportion of patients with visual loss in GCA varies depending on the GCA case-finding method and method of ascertainment of visual loss; for example, in a UK study recruiting from a rheumatology setting, 17% of 271 patients with GCA reported irreversible visual loss, and 1% had stroke(7). Headache, scalp tenderness, jaw claudication, visual loss and stroke are all classified as cranial manifestations of GCA(4). In addition, inflammation of the aorta and/or its proximal branches is common in GCA; this is often called large-vessel vasculitis outside the head and neck (LV-GCA), and may be asymptomatic or produce non-specific systemic symptoms, such as fever or weight loss. Vascular imaging in GCA demonstrates large-vessel involvement, usually with some degree of aortitis, in up to 83% of cases(8). This large-vessel inflammation may lead to later development of vascular stenosis, aneurysm or dilatation, dissection or rupture (9). A subset of patients with LV-GCA presents with symptoms of a systemic inflammatory syndrome, which can have features of polymyalgia rheumatica (PMR) without the classical cranial clinical features of GCA(4). The true prevalence of this is unknown, as vascular imaging is not routinely performed in PMR at presentation.

2. Need for the guidelines

As GCA is considered a medical emergency, it is treated at the point of diagnosis by clinicians in primary and secondary care who have a wide variety of clinical backgrounds. It is therefore necessary to provide clear guidance about current best practice, and the underlying evidence including areas of uncertainty.

Recent years have seen new evidence emerge regarding diagnosis and treatment of GCA. For this reason, major revision to the 2010 BSR Guidelines for the management of GCA (10) was required. We also broadened the remit of the previous guideline to include diagnostic imaging for GCA.

3

3. Objectives of guideline

To provide guidance for clinicians in the diagnosis and treatment of GCA. This guideline is supported by evidence wherever some evidence exists, and by expert consensus where current evidence alone cannot provide a definite answer. The patient population covered by this guideline includes those patients in whom GCA is suspected sufficiently strongly that a decision to initiate glucocorticoid treatment is made. These guidelines are not limited to GCA related temporal (cranial) arteritis but include also patients presenting with LV-GCA and limited forms of GCA with or without an association with polymyalgia rheumatica (PMR).

The evidence search was restricted to adult humans with GCA or suspected GCA, not limited by ethnicity, age or sex; however, as GCA is extremely rare in patients under 50 years[1], generalisability below this age limit cannot be assured.

4. Areas the guideline does not cover

Takayasu arteritis and other forms of vasculitis (e.g. secondary large-vessel vasculitis) are not covered by this guideline. The treatment of uncomplicated PMR is outside the scope of this guideline; readers are referred to the most recent BSR and ACR/EULAR guidance on management of PMR[11, 12]. Guidance regarding immunisations and prophylaxis of glucocorticoid-induced osteoporosis is available elsewhere[13, 14].

5. Target audience

This guideline is intended for doctors and allied health professionals who work in a primary or secondary care setting and manage patients with suspected and/or established GCA. From a diagnostic perspective, early recognition of suspected GCA by the non-specialist is encouraged, but definitive diagnosis of GCA can be challenging and therefore prompt onward referral to an appropriate specialist is recommended. From a treatment

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

perspective, this guideline is intended to provide a framework by which specialists, general

practitioners and patients can work together to deliver optimal care tailored to the

individual patient.

Stakeholder involvement

The guideline was developed in accordance with the BSR Guidelines Protocol.

Members of the Working Group co-authored this guideline and are listed at the end of this document with their affiliations. Important stakeholder representation included patient groups (PMRGCAuk, PMR and GCA North East, PMR-GCA Scotland) and the Royal College of Ophthalmology. Individuals on the Working Group had a range of expertise including rheumatology, general practice, ophthalmology, specialist rheumatology nursing, and systematic review and guideline development methodology, and included patients with personal experience of GCA. There was no representation from industry. Informal feedback was sought at open meetings held at several international rheumatology conferences to ensure that the guideline development process took account of current practice and important clinical questions within the wider rheumatology community, particularly regarding general principles of management.

Prior to defining the Population-Intervention-Comparator-Outcome (PICO) questions, stakeholders were consulted regarding outcomes of importance in GCA(15).

A list of candidate outcomes was identified after feedback from all the stakeholders and from a scoping literature review. A survey was undertaken to prioritise candidate outcomes. A total of 67 patients, 45 rheumatologists, 10 generalists (general practitioners or hospital based) and 7 ophthalmologists responded to the questionnaire. Each outcome was graded based on its relative importance for clinical decision-making on a 1 to 9 point scale(15). Scores from 1-3 indicated limited importance (not important for decision making), 4-6 important (important, but not critical for decision making) and 7-9 critical (critical for decision making). Outcomes deemed as critical (i.e. score ≥7) by at least 70% of physicians and/or patients were considered as candidate outcome measures and this list was refined by the Guideline Working Group for the purpose of defining a list of "outcomes" for the PICO questions (Appendix B).

The GCA Guideline Working Group developed the PICO questions, discussed the evidence collated, iteratively refined the wording of draft recommendations and voted on the final recommendations.

Rigour of Development

1. Scope of literature search and strategy employed

PICO questions

The systematic literature search was directed according to pre-defined questions in PICO (Population, Intervention, Comparator, Outcome). These were written by the Working Group and feedback was explicitly invited from the patients within the group. The PICO questions were structured as follows:

1. For recommendations on diagnostic imaging tests, the (P) target population comprises patients with suspected GCA, the (I) intervention is the diagnostic test of interest, the (C) comparator is the comparator test or the reference standard, and the (O) outcomes are true positives, true negatives, false positives, false negatives, complications related to test, resource use, inconclusive results and the implication of these items on patient-important outcomes as listed below(16).

2. For recommendations on treatment, the (P) target population comprises patients with a diagnosis of GCA/patients with a high suspicion of GCA above the treatment threshold, (I) intervention and (C) comparator are the alternative management strategies, (O) outcomes listed below(16).

3. For prognostic factors, the (P) target population comprises patients with a diagnosis of GCA, (I) the presence and (C) the absence of a prognostic factor, (O) outcomes listed below(17).

 A preliminary list of PICO questions was identified by a face-to-face discussion at the first guideline development group meeting followed by an e-mail based survey of the Working Group. These preliminary questions were refined and grouped together where appropriate at the second guideline development group meeting. This resulted in a final list of PICO questions (Appendix C).

The PICO questions were used to formulate a protocol for the systematic review, which was approved by BSR before commencing searches. Screening of the search output was performed by two group members for each topic (diagnostic tests: C. Duftner, S. Appenzeller; therapeutic strategies: C. Dejaco, D. Camellino; prognostic factors: S. Gonzalez-Chiappe, A.W. de Souza) who independently selected full texts, extracted data and performed quality appraisal. Any disagreements between these two group members were resolved by discussion, consulting a third member (S. Mackie, A. Hutchings or A. Mahr, respectively) where no consensus could be reached. The literature search was last updated on 18th June 2018 by G. Reynolds and the outputs appraised by the same group members as before for consistency.

The search strategy of electronic databases is given in Appendix D. Further published studies were identified by hand-searching the reference list of full and review articles and by contacting experts in the field. In addition to this, ClinicalTrials.gov, ISRCTN and EU Clinical Trials Register were searched, and the literature tracked to identify published trial results.

Criteria for selecting articles for full-text review are given below.

Diagnostic studies: We included full research articles of prospective studies involving >20 patients and investigating the index test in patients with suspected GCA. We did not evaluate temporal artery biopsy as an index test because of incorporation bias in relation to the reference standard. We excluded diagnostic case-control studies because this type of study design produces estimates of diagnostic accuracy that are not applicable to routine clinical practice(18); studies where the index (imaging) test had been performed in >10% of patients upon treatment with glucocorticoids for >1 week (because imaging tests for GCA suffer significant loss of sensitivity after commencing high-dose glucocorticoids; having an imaging test within 1 week of initiating glucocorticoids appears feasible in practice(19)); studies with a reference standard other than clinical diagnosis (without formal criteria), ACR classification criteria and/or temporal artery biopsy result; and studies that could not be assigned to any of the PICO questions.

Interventional studies: We included randomized controlled trials involving >20 patients with GCA. Observational or non-randomised studies, or studies that could not be assigned to any of the interventional PICO questions, were excluded.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Prognostic studies: We included prospective and retrospective studies on >100 GCA patients investigating primarily the relevance of any of the prognostic factors of interest. Studies with another research focus (e.g. description of a cohort, interventional trials) were excluded for this part of the SLR. We further excluded studies that did not report the result of a statistical test for association with the outcome. The prognostic factors being investigated should have been in routine clinical use without requiring sophisticated equipment or complex analysis. A minimum time for follow-up in eligible studies was set at 6 months. Because the aim of this part of the SLR was to identify factors that could be used to risk-stratify patients in routine clinical practice, studies that reported exclusively on imaging or laboratory tests with no reference to patient presentation were excluded.

Data extraction

Study details and results were extracted using a data extraction form from included articles by two members of the literature review team according to GRADE methodology[20]. The preliminary data extraction form was piloted in 5 identified articles and evaluated for completeness and handling. This data extraction form included the following items: authorship and publication, design, main study population, primary study objective(s), links/overlap with other studies, study inclusion criteria, characteristics of participants, definition of intervention/exposure and control, definition of outcome, method of statistical analysis, length of follow-up, losses to follow-up, missing data, discrete/continuous data (counts, means, standard deviations etc.), measures of effect and uncertainty, and any other information relevant to quality assessment. Additional parameters extracted relevant to diagnostic studies included use of glucocorticoids before performance of imaging, disease characteristics (number (%) of patients fulfilling clinical criteria for GCA, number (%) of patients with positive temporal artery biopsy, number (%) of patients with large-vessel GCA), technical aspects (imaging devices used, elementary lesions and structures investigated, blinding of the index test to reference standard), index test, reference standard, diagnostic performance (raw data to calculate sensitivity, specificity, positive (LR+) and negative likelihood ratio (LR-)) and parameters required for assessment of study quality (risk of bias). Additional data extracted relevant to prognostic factors included adjusted and

9

unadjusted odds ratios, relative risks or hazard ratios, and information relevant to quality assessment.

Quality assessment

We evaluated the quality of evidence using the approach set out by GRADE(20, 21), implemented as follows:

1. Risk of bias: Confidence in the estimate of the effect decreases if studies have major limitations that may bias their results. For diagnostic studies, risk of bias was assessed using the QUADAS-2 tool(22) . For interventional studies, the following factors were considered(20): randomisation procedure and sequence generation; allocation concealment; blinding of patients and assessor; completeness of outcome reporting (attrition bias: losses of follow-up, adherence to the intention to treat analysis or stopping the trial early for benefit); selective outcome reporting. For prognostic studies, risk of bias was investigated using the following questions(17):

   1. Was there a representative and well-defined sample of patients? Was selection bias avoided?

   2. Was follow-up sufficiently long and complete?

   3. Were objective and unbiased outcome criteria used? Were methods used to determine/measure outcomes adequate?

   4. Were all characteristics of patients known or suspected to affect the outcome recorded?

   5. Was there adjustment for important prognostic factors, including age, sex, ESR, ischemic manifestations (amaurosis fugax, jaw claudication, limb claudication) extracranial manifestations, symptom duration, comorbidities, constitutional symptoms, smoking?

2. Inconsistency of results: Confidence of the estimate of the effect decreases if there is variability in results (heterogeneity) across studies and investigators fail to identify a plausible explanation.

3. Indirectness of the evidence: Confidence of the estimate of the effect decreases if there are differences between the population, intervention, comparator or outcome of interest, and those included in the systematic review studies.

4. Imprecision: Confidence of the estimate of the effect decreases if the systematic review includes relatively few patients and few events and thus has wide confidence intervals and/or the extremes of the confidence intervals are close to the null effect.

5. Publication bias: Confidence of the estimate of the effect decreases if there is evidence that some studies were not reported.

Evidence generated from prospective diagnostic accuracy studies, randomized controlled trials and longitudinal cohort studies investigating prognostic factors started as high quality but was downgraded if any of the above limitations was present.

After assessing these five domains the overall QoE was assessed as:

1. High quality evidence (indicated by ++++ (A) – further research is very unlikely to change our confidence in the estimate of effect)

2. Moderate quality (indicated by +++ (B) – further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate)

3. Low quality (indicated by ++ (C) – further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate)

4. Very low quality (indicated by + (D) – any estimate of effect is very uncertain)

Preparing the evidence report

Evidence tables were prepared by the literature review team for each PICO question using Review Manager (RevMan) and GRADE profiler (GRADEpro) software.

The evidence profiles contained the following specific information:

Diagnostic studies: Direct outcomes (true positives, true negatives, false positives, false negatives, sensitivities and specificities; complications of the index test and of the reference

standard; resource use), the number of studies and quality assessment related to each of

these outcomes and the effect estimate (i.e. number of individuals classified per 1000

people) according to different pre-test probabilities (low (<20%), intermediate (20-50%) and

high (>50%) pre-test probability).

<u>Interventional studies</u>: Benefits and harms for each outcome across studies, the assumed

and corresponding risk for comparators and interventions (95% confidence interval (95%

CI)), the absolute and relative effect (95% CI), the number of participants / number of

studies, and number needed to treat, and the QoE including quality factors for each critical
and important outcome.

<u>Prognostic studies</u>: Odds ratios, relative risks or hazard ratios were extracted as well as

corresponding p-values, both unadjusted and (where available) adjusted for confounders.
Results of quality appraisal were also reported.

Whenever possible, meta-analyses using fixed effect methods (interventional studies) or

random-effect methods (diagnostic, prognostic studies) were conducted to combine the
results of studies for each PICO question.

Statistical heterogeneity was assessed by considering the chi-squared test for significance at

$p<0.1$ and I-squared inconsistency statistic of >50% to indicate significant heterogeneity.
Where significant clinical heterogeneity was present, analysis of individual studies and/or

sub-analyses investigating studies with comparable design and quality was conducted.

2. Methods used to formulate the recommendations

General Principles statements

GRADE recommends that where certain principles of diagnosis and treatment of a disease

are generally agreed by the medical community, these should be stated in terms of "good
practice statements"(23). Here we call these "General Principles" and are a description of

generally-accepted best medical practice as evidenced by consensus within our Guideline

Working Group. They are not necessarily evidence-based but form the clinical context

within which the evidence-based recommendations should be understood.

General Principles statements in relation to GCA were drafted and iteratively refined by means of multiple rounds of email consultation within the Guideline Working Group, including patient representatives, as well as wider consultation by presentation and discussion at international rheumatology meetings. The final versions were voted on by the Working Group and a consensus score generated for each statement, defined as the mean value of scores of all the individual Working Group members.

Forming guideline recommendations

Using the Evidence Profiles, recommendations were proposed for each key question according to the GRADE methodology(24):

The GRADE system offers two grades of recommendations: "strong" and "conditional".

This grade is determined by 1) QoE, 2) balance between desirable and undesirable effects, 3) values and preferences of patients, and 4) use of resources.

The evidence on prognostic factors was used to build subgroups of GCA patients with different risk profiles concerning patients' important outcomes rather than formulating individual recommendations on prognostic factors. Treatment recommendations have been tailored to these subgroups given that the tradeoff between benefit and harm, values and preferences as well as consideration regarding resource use may vary according to the presence or absence of risk factors.

The recommendations process was conducted in two stages:

I)   The quality of evidence was discussed at international meetings and webinars

II)   Recommendations were formulated which were iteratively refined via webinars and email.

Finally, the Working Group voted by scoring each recommendation on a 0-10 scale. The consensus score was defined as the mean of all scores received.

The quality of overall evidence for each recommendation was summarised using the GRADE QoE scale, as per the BSR Guidelines Protocol 2017.

3. Limits of search and search dates

The following electronic databases were searched from their inception dates, noted in parentheses, to present: Ovid MEDLINE (1946), EMBASE (1988), Cochrane Central Register of Controlled Trials (1996), and Cochrane Systematic Reviews (1993). The search was last updated on 23rd June, 2018.

Because of the need for quality appraisal by a consistent team of reviewers, the search was limited to articles published in English.

4. When will the Guideline be updated?

The Guideline will be updated after three years; publication of a major new clinical trial may trigger a partial revision.

The Guideline

Eligibility

- Patients with suspected giant cell arteritis (for diagnostic tests)

- Patients with confirmed giant cell arteritis (for treatment recommendations)

Exclusions
- Takayasu arteritis

- Polymyalgia rheumatica (unless there is also a diagnosis of giant cell arteritis)

General Principles

 "General Principles" are not the same as evidence-based recommendations, but are presented here to summarise best practice.

How should suspected GCA be treated?

1. Patients in whom GCA is strongly suspected should be immediately treated with high-dose glucocorticoids. Consensus score: 9.61

"Strongly suspected" GCA means that in the assessing clinician's judgement, GCA is a more likely explanation for the patient's symptoms than any other condition. The assessing clinician may take into account GCA symptoms, signs and laboratory tests (such as acute phase markers) (25, 26). The risk of toxicity caused by short-term glucocorticoid treatment commenced in patients with initial strong suspicion of GCA but then diagnosed with an alternative condition, is acceptably low as long as a full diagnostic evaluation is performed promptly and it is acknowledged that a suspicion of GCA is not the same as a diagnosis of GCA. For doses, see below.

How quickly should patients with suspected GCA be referred for evaluation?

2. GCA is a medical emergency. Each local healthcare organisation should have information available to front-line clinicians, such as general practitioners and clinicians working in acute care, on how to refer patients with suspected GCA urgently for local specialist evaluation: patients should be evaluated by a specialist ideally on the same working day if possible and in all cases within 3 working days. Consensus score: 9.17.

Rapid specialist evaluation is a key principle of management of GCA; therefore, "fast-track" referral pathways for urgent specialist evaluation of suspected GCA are beneficial. On suspicion of GCA, primary care providers should initiate glucocorticoids alongside an urgent referral to the local GCA pathway. In retrospective reports from centres that have set up "fast-track" referral pathways, initial diagnostic evaluation and treatment of patients with suspected GCA within 24 hours of referral has been associated with reduction of reported rates of GCA-related sight loss, compared to conventional care pathways(27, 28). In a prospective, multicentre UK study, clinical evaluation, vascular ultrasound and temporal artery biopsy were all undertaken within one week of commencing high-dose glucocorticoid therapy for suspected GCA (19). The success of "fast-track" referral pathways depends on appropriate selection of patients for referral, and therefore education of clinicians in primary and secondary care is crucial.

To whom should patients with suspected GCA be referred?

3. Patients with suspected GCA should be evaluated by a clinician with appropriate specialist expertise, usually a rheumatologist. Patients presenting with a history of new visual loss (transient or permanent) or double vision should be evaluated as soon as possible on the same calendar day by an ophthalmologist. Consensus score: 9.61.

The reason for needing a full, prompt diagnostic evaluation by a clinician with appropriate specialist expertise is that undiscerning use of high-dose glucocorticoids may mask other diseases and can complicate the diagnostic work-up(12, 25). Where the diagnosis is difficult, opinions from specialists from multiple disciplines can be of value. This includes the interpretation of specialised investigations for GCA and the consideration of alternative diagnoses. Ophthalmological evaluation is essential where there is visual loss, of which there are various possible causes in GCA (29, 30).

What evaluations should be performed when starting treatment?

4. When starting glucocorticoids for suspected GCA, diagnostically relevant symptoms and signs should be documented. Blood should be taken for full blood count, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) before or immediately after commencing high-dose glucocorticoids. If GCA is strongly suspected, the first dose of glucocorticoid can be given without waiting for laboratory results. Consensus score: 9.61

Diagnostically relevant symptoms and signs of GCA include headache; scalp hyperaesthesia; jaw or tongue claudication; temporal artery tenderness, nodularity or reduced pulsation; visual manifestations including diplopia or changes to colour vision; limb claudication; polymyalgia rheumatica (pain and stiffness of shoulder and hip girdles); fever, sweats or weight loss. Less commonly, patients may have carotidynia, audiovestibular symptoms, dry cough, or indications of tongue or scalp ischaemia that may precede necrosis. However, as none of the above-mentioned symptoms is entirely specific (or pathognomonic) for GCA, and many are very non-specific, each is of limited use if taken in isolation(26), and the differential diagnosis must also be considered. GCA causes elevation in platelet count, CRP and ESR. Plasma viscosity can be used where ESR is unavailable. These markers all fall with

glucocorticoid therapy; therefore, all patients should have blood drawn prior to starting treatment, unless there is evidence of critical ischaemia such as visual loss or diplopia and no immediate access to phlebotomy.

What evaluations should be performed soon after starting treatment for GCA?

5. Patients treated for GCA should be evaluated for features of the disease relevant to prognosis, such as clinical and laboratory features of a marked inflammatory response at diagnosis, ischaemic manifestations such as transient visual loss or jaw/tongue claudication, and signs or symptoms indicating involvement of the aorta and its proximal branches; and for co-morbidities relevant to treatment, such as diabetes mellitus, hypertension, and bone fracture risk. Consensus score: 9.53

Assessments to be performed in all patients with GCA are detailed in table 1. As well as confirmatory tests for GCA (see Key Recommendation 1), alternative explanations for patients' symptoms should be considered, particularly if these confirmatory tests are negative. Factors relating to prognosis (risk factors (prognostic) PICO questions 1-6) were reviewed; overall, insufficient evidence was found to be able to stratify patients with proven GCA to different management strategies on the basis of risk factors considered: age, sex, acute phase reactants, PMR status, large-vessel involvement in GCA, atherosclerotic disease, glucocorticoid responsiveness or histological features of GCA. Nonetheless these features remain important diagnostically and/or when assessing for risk of glucocorticoid-associated adverse effects.

Risk factors for visual loss: Studies reporting risk factors for permanent visual loss in GCA yield variable results. In a single-centre study of 339 consecutive biopsy-proven cases presenting over a 39-year period, in which clinical features were prospectively recorded by an internist in a 176-item structured questionnaire, 53 patients had permanent visual loss. In multivariable regression modelling, older age, history of transient visual loss and jaw claudication were independent predictors of visual loss, while fever and rheumatic symptoms were protective(31). Similar findings were reported in an earlier retrospective study of irreversible cranial ischaemic complications in 200 patients, with transient diplopia also identified as a potential risk factor(32). Hypertension and ischaemic heart disease were also identified as potential risk factors for cranial ischaemic complications in studies from

17

Italy and Spain(33, 34). In an international multicentre observational study reporting data from 433 GCA patients from 26 countries, 34 patients developed complete loss of vision in one or both eyes at 6 months. After adjusting for age and sex, the strongest risk factor for this was peripheral vascular disease recorded at baseline (the effect size was similar when restricting the case definition to biopsy proven GCA)(35).

Risk factors for aortic aneurysms: Inflammation of the aorta is associated with subsequent development of aortic dilatation or aneurysm(36); and those GCA patients with dilatation of the subclavian arteries were found to be more likely to develop aortic aneurysm later than those with GCA-related subclavian stenosis(37). Possible risk factors for aneurysm development in GCA are smoking, male sex, hypertension, and pre-existing cardiovascular disease as well as inflammation of the aorta or its proximal branches(37-41). However, the evidence about risk factors for aneurysm development in GCA is not at present sufficient to define high risk subgroups to select GCA patient subgroups for aortic imaging. Chest radiography involves minimal radiation exposure but is insensitive to early thoracic aortic aneurysms(42). French recommendations suggest routine aortic imaging at GCA diagnosis and every 2-5 years thereafter(43). However, aortic imaging as a routine screening test for all GCA patients remains of uncertain cost-effectiveness and the optimal method and timing of imaging in this context is still unclear(44). Therefore clinicians are advised to use their own discretion regarding selection of patients for aortic imaging.

Risk factors for prolonged treatment course: A "strong inflammatory response" (defined as three or four of the following features: fever, weight loss, ESR≥85mm/hour, and haemoglobin<11g/dL) has been associated with higher relapse rate and prolonged treatment course(45-47). Imaging evidence of LV-GCA may be associated with prolonged glucocorticoid treatment compared with patients with cranial GCA who did not have imaging evidence of LV-GCA (36, 48).

It is best practice for the prescriber of glucocorticoid therapy to ensure that patients are evaluated for hypertension and hyperglycaemia (blood glucose for acute changes and/or HbA1c to identify patients that might be at greater risk) within the first 2 weeks of commencing high-dose glucocorticoids. Comorbidities relevant to glucocorticoid toxicity

include diabetes mellitus, osteoporosis and bone fracture; generally, toxicity increases with glucocorticoid dose and duration(49). Symptoms of and/or exposure to serious infections should be assessed in all patients starting glucocorticoids, considering local prevalence of these infections; it is suggested that a chest radiograph and dipstick urinalysis should be performed. Exposure to TB should be discussed and screened according to national guidelines(50).

Oral glucocorticoids can rarely increase intraocular pressure or worsen pre-existing primary open angle glaucoma. If there is glaucoma or ocular hypertension present, or history of being a glaucoma suspect or glaucomatous risk factors (such as connective tissue disease, type I diabetes, a first-degree relative with primary open-angle glaucoma, or high myopia), screening should be performed by a suitably trained eye professional(51).

For ongoing care via a shared care model, patients with GCA should see a clinician with appropriate expertise at least every 2-8 weeks during the first six months, then every 12 weeks during the second six months, every 12-24 weeks during the second year, and additionally as indicated in case of relapse or as glucocorticoid therapy is tapered and discontinued. This visit schedule is based on the higher likelihood of new treatment-related adverse events and need for treatment dose adjustment early in the treatment course, while glucocorticoid doses are still high. However, this should be adapted for the individual patient. Each follow-up visit should include at least a full history, targeted physical examination and measurement of at least full blood count, ESR and/or CRP, plus follow up of any abnormalities relevant to the individual patient as well as drug-specific screening for toxicity.

How should ongoing management of GCA be individualised?

6. Full assessment of the disease and co-morbidities, and consideration of the patient's personal priorities, should inform decisions about glucocorticoid tapering and initiation of additional treatments such as glucocorticoid-sparing therapies. Involvement of, and clear communication with, primary care physicians is critical especially for management of multimorbidity. Consensus score: 9.67

Management of patients with GCA should include attention to co-morbidities and the impact of glucocorticoid toxicities in order to individualise the standard glucocorticoid

tapering schedule (Table 2). PICO questions on the prevention of glucocorticoid-induced osteoporosis and immunisation in GCA were not included; there are published guidelines on these matters(13, 14). Although it is customary to co-prescribe proton pump inhibitors with high-dose glucocorticoid therapy, especially in older patients, it has recently been suggested that lower glucocorticoid doses may not always routinely need co-prescription of a proton pump inhibitor(52). Local or national guidance should be followed. Glucocorticoid therapy increases susceptibility to infections but may also decrease the efficacy of vaccinations; live vaccines are contra-indicated in patients receiving high-dose glucocorticoid therapy (>20 mg prednisolone daily for 2 weeks or longer)(53). Patients without a history of chicken pox (varicella zoster virus infection) should be advised to avoid close contact with people who have chickenpox or shingles, and to seek urgent medical advice if they have been exposed.

What education should patients be offered?

7. All patients with GCA should be provided with information about GCA and its treatment. Patients should receive advice on diet, physical activity and stopping smoking. Consensus score: 9.47.

Information should be available at least in written format and ideally in multiple formats. Dietary considerations include mitigating the potential effects of glucocorticoid therapy on body weight, post-prandial glycaemia and bone fracture risk. Recommendations on physical activity in inflammatory arthritis and osteoarthritis are available (54) and there have also been suggestions of benefit in other inflammatory vascular diseases(55) but advice needs to be tailored to the individual patient with GCA, particularly if there are comorbidities. Particular considerations in GCA may include physical deconditioning as a result of the inflammatory disease, vascular stenosis to the limbs and the role of exercise in stimulating collateral formation, and the psychological benefits of exercise in mitigating the impact of the disease on the patient. Particular considerations with patients receiving long-term glucocorticoid treatment may include myopathy, which typically develops after weeks or months of glucocorticoid therapy (particularly at high doses); insulin resistance limiting the ability of skeletal muscle to take up glucose and store glycogen; bone fragility; and central adiposity. Exercise can also be beneficial for improving balance and general mobility, which may be affected by alterations to vision and biomechanics. The role of exercise programmes in GCA has not been formally evaluated in clinical studies. Patients should be signposted to

relevant patient support groups or charities as sources of peer support. Patients should be advised of potential symptoms of glucocorticoid withdrawal, although these are uncommon in practice. Patients should be advised about alteration of glucocorticoid dose in intercurrent illness, especially including advice for seeking emergency attention if they suffer a vomiting illness necessitating parenteral glucocorticoid.

What plans should be made for possible future GCA relapses?

> 8. During glucocorticoid taper and after glucocorticoid cessation, patients should be informed what symptoms may suggest GCA relapse and what action the patient should take in these circumstances, including first point of contact for medical advice and how to contact the team providing specialist care. Consensus score: 9.81

Examples of actions to consider if new GCA-attributable symptoms develop are given in Table 3.

Specific recommendations for diagnostic tests in suspected GCA

As affirmed in the 2010 BSR/BHPR guideline, there is an urgent need for confirmation of disease in every suspected case of GCA (10). In the 2010 guidance, it was recommended that temporal artery biopsy (TAB) was desirable in every case of suspected GCA. In this edition, this recommendation has been updated in view of new evidence regarding imaging tests for diagnosis of GCA.

Which additional confirmatory diagnostic tests should be performed in all patients with suspected GCA? (PICO 1, 2)

Diagnostic accuracy may be expressed as sensitivity or specificity, or as likelihood ratios; this information can be combined with the pre-test probability (established on clinical grounds) to select and interpret the results of confirmatory diagnostic tests. Compared to biopsy, imaging tests such as ultrasound have the advantage of access to both superficial temporal arteries in their entirety. Most diagnostic accuracy studies have focused on the role of

ultrasound (n=16) or MRI (n=7). One study addressed the role of FDG-PET, and another study examined the role of FDG-PET and CT angiography for GCA diagnosis.

Seven studies (519 patients with suspected GCA, of whom 169 were diagnosed with GCA) compared the ultrasound 'halo' sign with a clinical diagnosis of GCA, giving a pooled sensitivity of 79% (95% CI: 73%-84%) and pooled specificity of 94% (95% CI: 90%-96%) (56-62). Quality of evidence (QoE) was +++; downgrading was performed because of risk of bias in 4/7 studies. One of these studies included 12 patients with a final diagnosis of LV-GCA(57).

Five studies (185 patients with suspected GCA, of whom 57 were diagnosed with GCA) compared the ultrasound 'halo' sign with temporal artery biopsy, giving a pooled sensitivity of 74% (95% CI: 63%-83%) and pooled specificity of 81% (95% CI: 73%-88%) (60-64). QoE was +; downgrading was performed because of high risk of bias in all 5 studies, and because of inconsistency. Patients with LV-GCA were not evaluated in these studies.

Two studies (140 patients with suspected GCA, of whom 67 were diagnosed with GCA) compared the ultrasound 'compression' sign of temporal arteries with ACR criteria-based diagnosis of GCA, giving a pooled sensitivity of 79% (95% CI: 67%-88%) and a pooled specificity of 100% (95% CI: 95-100) (56, 65). QoE ++; downgrading was performed for risk of bias in one of the studies, and for the fact that both studies were performed by the same research group. The ACR criteria for GCA, which are not suitable for clinical diagnosis, served as reference standard in both studies.

Three studies (560 patients with suspected GCA, of whom 327 had a clinical diagnosis of GCA) compared the diagnostic performance of ultrasound abnormality (defined as any one of halo, stenosis or occlusion) with clinical diagnosis of GCA, giving a pooled sensitivity of 61% (95% CI: 56%-67%) and pooled specificity of 86% (95% CI: 81%-90%) (19, 62, 66). QoE ++; downgrading was performed for risk of bias in all three studies, and for inconsistency.

Four studies (563 patients with suspected GCA, of whom 180 had a positive temporal artery biopsy) compared the diagnostic performance of ultrasound abnormality (defined as any one of halo, stenosis or occlusion) with temporal artery biopsy, giving a pooled sensitivity of 81% (95% CI: 74%-86%) and pooled specificity of 74% (95% CI: 70%-79%) (19, 62, 66, 67).

QoE ++; downgrading was performed for risk of bias in three of the four studies, and for imprecision.

Neither clinical diagnosis nor temporal artery biopsy are perfect reference standards for evaluating the diagnostic accuracy of ultrasound for GCA, because neither of these are themselves 100% accurate. Clinical diagnosis is based on clinical symptoms, signs and laboratory tests, each of which are imperfect markers for GCA.

A positive temporal artery biopsy, showing features of inflammation characteristic of GCA such as giant cells or panarteritis(68), confirms the diagnosis of GCA. Although the true sensitivity of temporal artery biopsy is not precisely known, it is accepted that its sensitivity is substantially less than 100%; this is supported by the histological observation of skip lesions in some cases. An imperfect reference standard would result in underestimation of the diagnostic accuracy of ultrasound. When using clinical diagnosis as a reference standard it is important that this is made independently of the index test result in order to avoid bias; this may be done by blinding of the diagnostician to the index test result. Notably a large prospective UK study assessing the diagnostic value of ultrasound addressed this issue by blinding the patient, the treating clinician and the investigator to the ultrasound result (19). Ultrasound was found to be more sensitive but less specific than biopsy for diagnosis of GCA, was cost-effective and provided scope for reducing the number of patients who need a temporal artery biopsy(19). Overall, the pooled positive and negative likelihood ratios for ultrasound appear to support its use either for ruling out GCA in low-probability cases or for confirming GCA in high-probability cases (Appendix E and Figure 1). Ultrasound of the axillary arteries might add extra diagnostic information to ultrasound of the temporal arteries(69).

Six studies (500 patients with suspected GCA, of whom 268 were finally diagnosed with GCA) compared cranial artery MRI (vessel wall oedema and contrast enhancement) with clinical diagnosis, giving a pooled sensitivity of 75% (95% CI: 69%-80%) and a pooled specificity of 89% (95% CI: 84%-93%) (70-75). QoE ++; downgrading was performed for risk of bias in five of the studies, and for the fact that five of the six studies were performed by the same research group; sensitivity was somewhat lower in the study performed by a separate group(75).

Five studies (397 patients with suspected GCA, of whom 171 had positive temporal artery biopsy) compared cranial artery MRI (vessel wall oedema and contrast enhancement) with temporal artery biopsy, giving a pooled sensitivity of 94% (95% CI: 90%-97%) and specificity of 79% (95% CI: 73%-84%) (70-73, 75). QoE +; downgrading was performed for risk of bias in five of the studies, for inconsistency, and for likely publication bias.

Overall, MRI of the cranial arteries appears to be potentially useful for ruling out GCA if the result if negative, but false positive test results could occur, such that MRI of the cranial arteries would not be first choice for a confirmatory test in GCA(75). Other issues of relevance to cranial vascular MRI are low availability of high-resolution 3T MRI equipment and expertise, higher costs and possible adverse effects of contrast agents.

In contrast to the 2010 guideline, where the authors outlined that imaging techniques are promising for diagnosis and monitoring of GCA(10), in this guideline there is now sufficient evidence, taken together, to state that all patients with GCA should have at least one confirmatory diagnostic test, which could be either temporal artery biopsy, or temporal and axillary artery ultrasound. However, temporal artery biopsy and ultrasound differ in their positive and negative likelihood ratios for GCA, with biopsy having relatively greater "rule-in" value and ultrasound having relatively greater "rule-out" value (Appendix E). Selection of the most appropriate confirmatory diagnostic test(s) therefore requires an assessment of the pre-test probability as outlined elsewhere(76); if both ultrasound and biopsy are possible, an approach to this is suggested in Figure 1.

The ultrasound halo diminishes in size during the first week of glucocorticoid therapy, indicating that sensitivity of the test is likely to depend on the delay between initiation of glucocorticoid therapy and the ultrasound test(19). Ultrasound is operator-dependent and requires adequate training. Ultrasound performs best in the "fast-track" setting, assuming rapid access, good technical equipment and high expertise with this method. With ultrasound, the non-compressible 'halo' sign is the most important finding suggesting GCA(77). Temporal artery biopsy should be performed by a surgeon experienced in this procedure, and samples should be at least 1cm in length post-fixation. The pathologist evaluating the biopsy should be experienced in diagnosing GCA. Data from the TABUL study(19) suggested significant variation between pathologists in the interpretation of temporal artery biopsy histology, so where biopsy findings are ambiguous (eg low-level

inflammation restricted to the adventitia), discussion between the requesting clinician and the pathologist is desirable. In the absence of inflammatory infiltrate, a report of healed arteritis is not sufficient to diagnose GCA. Isolated vasa vasorum vasculitis is not diagnostic of GCA. Contralateral biopsy may slightly increase the yield of temporal artery biopsy, but is usually unnecessary. Biopsy may remain positive for several weeks after initiation of glucocorticoid therapy (78).

If neither vascular ultrasound nor biopsy is possible, and local MRI facilities and radiology support are available, then high-resolution 3 Tesla MRI of the cranial arteries could be used instead. In interpreting the results of these diagnostic tests, pre-test probability (established on clinical grounds) should be taken into account (Figure 1).

1. Strong recommendation: Patients with suspected GCA should have a confirmatory diagnostic test. This could be either a temporal artery biopsy at least 1cm in length, or an ultrasound of the temporal and axillary arteries, or both. QoE: +++ Consensus score: 9.33.

Which tests can be used to evaluate involvement of the aorta and its proximal branches in GCA? (PICO 2, 3)

One study (24 patients with suspected GCA, of whom 15 were diagnosed with GCA) compared FDG-PET with clinical diagnosis of GCA, giving a sensitivity of 67% (95% CI: 38%-88%) and a specificity of 100% (95% CI: 66% to 100%) (79). QoE ++; downgraded because of indirectness and publication bias.

One study (69 patients with suspected GCA/PMR, of whom 13 had biopsy evidence of GCA) compared vascular 18F-glucose uptake in thorax and legs on FDG-PET with temporal artery biopsy, giving a sensitivity of 77% (95% CI: 46% to 95%) and specificity of 66% (95% CI: 52% to 78%). Comparing vascular 18F-glucose uptake in thorax on FDG-PET with temporal artery biopsy gave a sensitivity of 54% (95% CI: 25% to 81%) and specificity of 86% (95% CI: 74% to 94%). QoE +; downgraded because of risk of bias, indirectness and imprecision (80).

One study (24 patients with suspected GCA, of which 15 were diagnosed with GCA) compared CT angiography (CTA) with clinical diagnosis of GCA, giving a sensitivity of 73% (95% CI: 45%-92%) and specificity of 78% (95% CI: 40%-97%) (79). QoE++; downgraded for indirectness and publication bias. CTA can reveal wall thickening with contrast enhancement in biopsy-proven GCA(81). There is also experience with CTA for accurate assessment of luminal diameter for large vessel stenosis in Takayasu arteritis (82).

No studies of MR angiography for the diagnosis of LV-GCA were found meeting our criteria, but there is experience with MRI for detection of vessel wall oedema reflective of inflammation and accurate assessment of luminal diameter for large vessel dilatation and stenosis in diseases of the major arteries, such as Takayasu arteritis. Gadolinium-enhanced MR angiography may help identify aortitis in the large-vessel vasculitides, but appears to be very sensitive to glucocorticoid therapy(83).

In addition to showing inflammation of the large vessels, FDG-PET-CT may detect malignancy or infection so can be of use in the differential diagnosis of GCA. Contrast-enhanced CT of the chest and abdomen is also often used in clinical practice to screen for deep infection or occult malignancy. Moreover, aortic wall thickening on a contrast CT might help to identify GCA, albeit with lower sensitivity than FDG-PET-CT, and could also potentially have uses in settings where FDG-PET-CT is unavailable(79, 84, 85). Additional advantages of FDG-PET and CT therefore include potential value in the workup of alternative diagnoses such as malignancy and infection.

As well as detecting axillary artery involvement for diagnosis of large-vessel involvement in GCA, vascular ultrasound may also be able to visualise the carotid arteries and obtain more limited views of the subclavian arteries, vertebral arteries, and parts of the aorta, but a higher level of operator expertise is required for these studies.

Overall, there is indirect evidence for the use of imaging tests to evaluate involvement of the aorta and its proximal branches in GCA, but the published evidence is extrapolated from other diseases such as Takayasu arteritis(76) and there is currently insufficient evidence

from prospective studies of suspected GCA to yield precise estimates of diagnostic accuracy for these tests.

2. Conditional recommendation: 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), magnetic resonance angiography (MRA), computed tomography angiography (CTA) or axillary artery ultrasound may be used to evaluate involvement of the aorta and its proximal branches. QoE: + Consensus score: 9.36.

Recommendations for treatment of GCA

What is the best dose and route of initial glucocorticoid therapy for GCA in the absence of ischaemic visual manifestations? (PICO 1-3)

There are no clinical trials comparing different initial oral glucocorticoid doses for GCA. However, clinical experience suggests that the vast majority of patients with GCA respond symptomatically within 1-7 days to a 40-60mg daily dose of prednisolone, apart from irreversible sequelae such as established visual loss, stroke or tissue necrosis. Failure to respond to this dose should prompt re-evaluation of the diagnosis.

In several clinical trials(86-88) the initial dose of oral prednisolone has been administered by weight rather than by a fixed dose, as is done for other systemic vasculitides in clinical practice. There was not enough direct evidence to be able to recommend dosing prednisolone strictly by mg/kg, but nonetheless body weight (or at least size) remains a factor to be taken into account when deciding on an initial dose. Comorbidities also should be taken into account, since the toxicity of glucocorticoid therapy increases with dose(49). Clinicians should consider a higher dose within the 40-60mg range for patients who have cranial ischaemic features of GCA such as ischaemic visual manifestations, jaw or tongue claudication, acknowledging that the evidence base for this is limited.

Two RCTs addressed the question of whether intravenous glucocorticoids should be given in patients with new-onset, uncomplicated GCA (i.e. those without any history of recent visual

loss, amaurosis fugax or transient ischaemic attack): one single-centre, 78-week double

blinded RCT (n=27) and one 12-month open RCT (n=164)(86, 89). In the double blinded

RCT(89), patients received either 15mg/kg body weight/day intravenous

methylprednisolone for 3 days or placebo plus 40mg/day oral prednisone. In the open

RCT(86), the intervention group was treated with a single dose of 240mg intravenous
methylprednisolone followed by 0.7mg/kg oral prednisone; one control group was treated

with oral prednisone 0.7mg/kg alone, and a further control group was treated with a single

dose of 240mg intravenous methylprednisolone followed by 0.5mg/kg oral prednisone. Due

to the substantial differences in study design, efficacy outcomes were not meta-analyzed.

We pooled the data for treatment related AEs to increase the power to detect unwanted

effects.

Moderate QoE (+++) from one study(89) suggested a reduction of the cumulative

glucocorticoid dose at week 78 (median cumulative glucocorticoid dose 5,636mg

(interquartile range 4,050-6,690mg) in the group that received three days of intravenous

methylprednisolone group, compared to 7,860mg (interquartile range 7,373-9,005mg) in

the control group). The glucocorticoid pulses were not counted for cumulative dose. In the

other study, very low QoE (+)(86) indicated no benefit of pulse treatment at 1, 2, 6 and 12
months regarding cumulative glucocorticoid dose.

Low QoE (++) suggested that those in the methylprednisolone group had a higher

probability of achieving remission while receiving 5mg oral prednisone or less at three

timepoints: week 36 (RR 4.64, CI 1.24-17.33), week 52 (RR 5.11, 1.39-18.81) and week 78

(RR 2.57, CI 1.12 to 5.89)(89).

No differences were found between pulse therapy and control groups as regards
discontinuation of glucocorticoids at 12 months (QoE +)(86), patients with at least 1 relapse
at 78 weeks and drug-free remission at 78 weeks (both with QoE ++)(89).

Comparing adverse events between treatment arms in these trials, no differences were

observed between intervention and control groups regarding infections, cushingoid habitus,

psychiatric side effects, cardiovascular complications, diabetes, digestive disturbances,

glucocorticoid-related ophthalmologic side effects, phlebitis/thrombosis, glucocorticoid

induced myopathy, abdominal bleeding, osteoporosis including fractures and mortality (all

with QoE + or ++). Nonetheless, the small size of these two trials limits power to show

significant differences in adverse events between treatment arms.

In summary, there may possibly be a small benefit in terms of a reduced cumulative

glucocorticoid dose in patients receiving glucocorticoid intravenous pulse therapy, but due
to concerns over the likely increased risk of adverse effects with this therapy, the value of

intravenous glucocorticoids in patients without acute or intermittent visual loss in GCA

remains uncertain.

3. **Conditional recommendation: The standard initial glucocorticoid dose for GCA is 40-60mg oral prednis(ol)one per day. QoE: + Consensus score: 9.44.**

What is the best dose and route of initial glucocorticoid therapy for GCA in the presence of

ischaemic visual manifestations? (PICO 4)

Clinical trials have not been conducted in patients with acute ocular ischaemia, but

observational data indicates that the vast majority of visual loss in GCA occurs before
initiation of glucocorticoid therapy. Acute visual loss due to ocular ischaemia in GCA

requires immediate action(29).

Intravenous glucocorticoid (methylprednisolone) therapy is used in systemic vasculitis for

the treatment of life- or organ-threatening disease(90). The intravenous formulation assures

rapid delivery of the drug to the site of action and in addition the very high doses required
have rapid actions via non-genomic effects, in addition to the genomic effects which take

some hours to affect gene transcription(91, 92). Intravenous glucocorticoid therapy is thus

commonly used for patients with acute or intermittent visual loss due to GCA. If intravenous

glucocorticoid therapy is not possible, 60-100mg oral prednisolone may be given for up to 3

consecutive days.

4. Conditional recommendation: GCA patients with acute or intermittent visual loss may

initially be given 500mg – 1g intravenous methylprednisolone daily for up to 3

consecutive days before commencing oral prednis(ol)one therapy. If intravenous

therapy is not immediately possible, this should not delay initiation of oral prednis(ol)one. QoE: + Consensus score: 9.00.

How should glucocorticoid dose be tapered in GCA? (PICO 5)

One single-centre, open, 2-month RCT compared different tapering regimens in 35 patients with new onset GCA(93). The same glucocorticoid dose was used in the first five days, but the rate of tapering thereafter differed between treatment groups. No significant difference was found between the groups at 2 months concerning relapse rate (QoE +) or visual loss (QoE ++).

In a multicentre RCT of tocilizumab as a glucocorticoid-sparing therapy for GCA(94), in two arms of the trial patients received placebo rather than tocilizumab. In one of these trial arms prednisone was tapered to zero over 6 months, and in the other of these trial arms prednisone was tapered to zero over 12 months; relapses were treated at the discretion of the investigator. Patients with new-onset GCA receiving the 6-month prednisone taper without tocilizumab had a numerically higher frequency of relapse during the first year than receiving the 12-month prednisone taper, whereas the cumulative glucocorticoid dose was similar in these two trial arms. Although patients and investigators were blinded to the tapering regimen, however, this trial was not designed specifically to compare different prednisone tapering regimens.

5. **Conditional recommendation: Glucocorticoid dose should be tapered to zero over 12-18 months, providing there is no return of GCA symptoms, signs or laboratory markers of inflammation. A more rapid dose reduction is appropriate for patients at high risk of glucocorticoid toxicity and/or those receiving concomitant glucocorticoid-sparing therapy. QoE: + Consensus score: 8.81.**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

What dosing frequency of oral glucocorticoid should be used in GCA? (PICO 6, 7)

One single-centre, open RCT with unclear length of follow-up compared the effects of 15mg oral prednisone every 8 hours with single administration of 45mg oral prednisolone/day. A third (alternate day) group received 90mg oral prednisone every other day. Patients in all three groups were treated for the first 5 days with 20mg oral prednisone every 8 hours(95).

Remission and relapses at 4 weeks did not differ between groups of split-dose and single-dose prednisone treatment (QoE +). No difference was reported regarding hypercortisolism (which was not further defined), fractures, diabetes and glucocorticoid-induced myopathy (all with QoE +).

Comparing the single-daily and alternate-day treatment groups, at 4 weeks the single-daily group had higher remission rates at 4 weeks (RR 2.67, CI 1.32-5.39) and lower relapse rates (RR 0.11, CI 0.02-0.80) (QoE +). Hypercortisolism was more common in the single-daily group (RR 5.95, CI 1.57-22.57); fractures, diabetes and glucocorticoid-induced myopathy (all with QoE +) did not differ between groups.

This evidence, albeit low quality, raises concerns that alternate-day dosing may be associated with a higher relapse risk. Splitting the dose over the day does not seem to confer benefit, and potentially carries risks of disturbance of diurnal rhythms, including sleep(96, 97). In summary there appears no reason in GCA to alter the standard guidance in other medical conditions to prescribe glucocorticoids as a single daily dose in the morning (12, 90).

6. Conditional recommendation: Patients should be prescribed a single daily dose of glucocorticoid, rather than alternate day dosing or divided daily dosing. QoE: + Consensus score: 9.53.

Should modified release prednisone be used in place of standard therapy? (PICO 8)

There was neither RCT data nor sufficient clinical experience to make any recommendation about modified release prednisone in GCA.

7. No recommendation can be made for the use of modified release prednisone in the treatment of GCA. QoE: insufficient evidence. Consensus score: 9.72.

When should further, non-biologic immunosuppression be added to glucocorticoid therapy for GCA? (PICO 9,10)

The effect of methotrexate (MTX) has been investigated in 3 RCTs: a single-centre, 24-month, double-blinded RCT (n=42) of patients with recent onset GCA compared the addition of MTX 10mg/week, versus placebo, to oral prednisone (initial prednisone dose of 60mg/day)(98). A multicentre, 12-month double-blinded RCT (n=98 instead of 300 originally planned) of patients with recent onset GCA compared the addition of MTX 15mg/week, versus placebo, to oral prednisone (initial prednisone dose of 1 mg/kg/day)(87). A smaller single-centre, double-blinded RCT (n=21), of patients with GCA whose prednisone dose had been reduced to 30mg/day, compared the adjunctive use of MTX 7.5 mg/week vs. placebo; the initial glucocorticoid dose was at the discretion of the treating physician and some patients with visual symptoms received intravenous glucocorticoid pulse therapy(99).

Regarding efficacy data, the two larger trials(87, 98) could be pooled but the smallest trial(99) was considered separately because it substantially differed from the two other trials regarding design (lower MTX dose used, initiation of therapy upon reduction of glucocorticoid dose) and quality. Regarding adverse events, we combined the data from all three trials events in order to increase the sensitivity to detect rare outcomes.

Pooling of the two larger studies indicated moderate QoE (+++) that MTX reduced the proportion with relapse at 12-24 months (RR 3.20, 95% CI 1.49 to 6.87)(87, 98); the smallest trial showed no difference in relapse between the MTX and placebo groups (QoE +)(99). In addition, the largest trial analysed "treatment failure", defined as having ≥2 relapses, or having a relapse that was not controlled by an increment of prednisone dose as scheduled:

regarding this outcome, no difference was seen between the MTX and placebo groups (QoE ++)(87). In none of the studies was a difference observed regarding cumulative glucocorticoid dose, or duration of glucocorticoid therapy (all outcomes with QoE + or ++); however, the largest trial reported only the median and interquartile range of cumulative glucocorticoid dose, rather than the mean and standard deviation, which reduced the validity of pooling the published data(87, 98, 99).

Regarding possible modification of glucocorticoid-related adverse effects by MTX: mortality, vision loss, malignancy, infections, psychiatric side effects, fractures, cataract, diabetes, hypertension, cushingoid habitus, weight gain and skin fragility did not differ between groups (data from 1-3 studies, all with QoE + or ++, except for hypertension which revealed a QoE +++)(87, 98, 99).

Regarding possible MTX-related adverse effects, there was no strong evidence to support that MTX was associated either with a higher rate of withdrawal due to any side-effect, nor an increase in individual side effects including ALT/AST elevation, nausea/vomiting, thrombocytopenia, oral ulcers, alopecia, diarrhea or gastric discomfort (QoE + or ++)(87, 98, 99). Nonetheless these trials were not designed nor powered to detect differences in adverse effects.

An individual patient data meta-analysis relating to these three RCTs was also identified(100) and included in this review because it is a more efficient use of the data than meta-analysis using published reports. According to the individual patient data meta-analysis, compared to the placebo group, the MTX group had a modest reduction of the risk of first and second relapse (hazard ratio (HR) 0.65, p=0.04 and HR 0.49, p=0.02, respectively), higher rates of glucocorticoid-free remission (HR 2.8, p=0.001 for ≥24 weeks sustained discontinuation of glucocorticoids) and lower cumulative glucocorticoid doses (mean difference -1.1g, p=0.007 at week 96)(100).

In summary, the data from these three small RCTs indicate that there might be a modest benefit of MTX in GCA in reducing relapse and cumulative glucocorticoid dose, and are encouraging regarding reducing the risk of second relapse as well as first relapse; however, overall the evidence remains equivocal. MTX has been used at doses of 7.5-15mg weekly in

33

clinical studies, and up to 25mg weekly, orally or by subcutaneous injection, in clinical practice.

One single-centre, 52-week, double-blinded RCT (n=31) compared azathioprine 150mg/day versus placebo in patients with PMR, with or without GCA, who required ≥5 mg daily oral prednisolone to control disease activity(101). A lower daily glucocorticoid dose at the end of the follow-up (52 weeks) was found in the intervention compared to the control group (mean dose difference 3 mg, CI 4.32-0.28mg, QoE +). Adverse events were similar in both groups (QoE +). Thirty-one patients were recruited, but only 18 reached the 52-week timepoint. According to the inclusion criteria for this trial, patients had to satisfy the Hazleman criteria for PMR. Eleven of 31 of these had a positive temporal artery biopsy. This trial did not truly fulfil the inclusion criteria for this review (at least 20 patients with GCA) and therefore no recommendation could be made on the basis of this trial; it is however included here for completeness since it is frequently mentioned by narrative reviews.

Dapsone was studied at a dose of 50-100mg/day in an open, multicenter RCT (n=47) with unclear length of follow-up(102). A lower relapse risk was found in the treatment compared to control group (RR 0.37, CI 0.16-0.84, QoE +), and there was a trend toward a higher probability of glucocorticoid-free remission (RR 3.81, CI 0.92-15.81, QoE +) in the dapsone group. Anaemia was more common in the dapsone group compared to the control group (RR 8.89, CI 1.27-61.99, QoE ++), and the dapsone group had two cases of agranulocytosis. Rash, diabetes, bone complications, cardiovascular complications, infections and loss of vision did not differ between groups (all QoE +).

Two open RCTs of ciclosporin (n=82) were published in the format of a letter(103, 104). Ciclosporin was used at a daily dose of 2.0-3.5mg/kg for 6 or 12 months. No benefit of the drug was observed regarding cumulative glucocorticoid dose, acute phase reactants as well as patients' and physicians' global assessments (all QoE +). There was, however, an increased risk of treatment discontinuation due to toxicity (RR 13.00, CI 1.78-95.1, QoE ++).

The potential toxicity of dapsone or ciclosporin is likely to outweigh any possible benefit and their use is not recommended.

There has been no RCT of leflunomide in GCA despite anecdotal evidence of benefit, case series and open, non-randomised studies (105-107). In clinical practice, mycophenolate mofetil or cyclophosphamide have been occasionally used as immunosuppressive agents for severe GCA by analogy with their use in other systemic vasculitides, but they have not been formally studied in GCA.

8. Conditional recommendation: Methotrexate might be considered for GCA, in combination with a glucocorticoid taper, in patients at high risk of glucocorticoid toxicity or who relapse. There is insufficient evidence to recommend any other oral immunosuppressive agent in GCA, including azathioprine, leflunomide or mycophenolate mofetil. QoE: ++ Consensus score: 8.92.

Which biologic agents can be used for GCA in addition to standard therapy? (PICO 11, 12)

Tocilizumab was approved for GCA by the US and European regulatory authorities in 2017 based on the results of two randomised controlled trials of addition of 1 year tocilizumab, or placebo, to tapering glucocorticoid therapy(88, 94).

In the larger of these trials(94), both patients with new GCA and patients with relapsing GCA were included. Patients with relapsing GCA had to have been treated for GCA for no more than 4 years prior to enrolment. Tocilizumab was combined with a standardised prednisone taper according to which prednisone cessation occurred at 6 months. Patients receiving placebo were treated with one of two alternative prednisone tapering schedules, by which prednisone cessation was achieved at either 6 months or 1 year if the patient remained relapse-free. If a patient relapsed during the study, prednisone therapy was escalated according to investigator discretion.

The primary endpoint (sustained remission at 1 year plus adherence to the tapering protocol, using a definition of remission incorporating CRP levels) was achieved in 56% of patients treated with weekly subcutaneous tocilizumab, and in 53% of those treated every other week. In the placebo group, sustained remission at 1 year was achieved in 14% of those tapering prednisone over 6 months and 18% of those tapering prednisone over 1 year. Comparing weekly tocilizumab with placebo plus 6-month glucocorticoid taper, relative risk (RR) for sustained remission was 4.0 (95 % CI 1.97 to 8.12, QoE++++).

Comparing with other groups revealed similar results, with RR 3.01 - 3.79, QoE ++++.

Patients in the tocilizumab treatment arm also showed a higher rate of sustained remission

using a modified definition of sustained remission that did not require CRP normalisation

(weekly tocilizumab compared with placebo plus 6-month glucocorticoid taper: RR 2.95,

95% CI 1.66 - 5.26, QoE +++, for other comparisons RR 1.65 – 2.76, QoE+++). In both this

trial and in the smaller single-centre trial(88), an increase in relapse-free survival at 1 year

(RR 3.57, 95% CI 2.29 - 5.55, QoE ++++) was seen, and a reduction in 1-year cumulative

glucocorticoid dose was observed in the tocilizumab treatment arms (mean difference 1434

mg lower (95% CI 2148 mg lower to 720 mg lower) in the weekly tocilizumab group

compared to placebo plus 6 month tapering of glucocorticoids, QoE++++; mean difference

from 1434mg to 1956 mg in other comparisons, QoE++++). Patient-reported outcomes were
encouraging although these were assessed using generic measures, since no disease-specific

patient-reported outcome has yet been fully validated for GCA. Of note, although

glucocorticoid-sparing efficacy was demonstrated, these studies were not designed or

powered to demonstrate a reduction in glucocorticoid-related adverse events.

It has been argued that a glucocorticoid-sparing therapy such as tocilizumab would be more

cost-effective in the following GCA patient subgroups: firstly, GCA patients requiring

escalation of glucocorticoid therapy due to relapse of disease, and secondly, GCA patients
who are at high risk for adverse effects from further glucocorticoid treatment (e.g. on the

basis of comorbidity profile or other risk factors for glucocorticoid-related toxicity: for

example, neuropsychiatric glucocorticoid-related adverse effects, previous fragility

fractures, or difficult-to-control diabetes mellitus). UK prescribers should be aware that, at

the time of writing, a limited duration of tocilizumab therapy for GCA has been approved by

the Scottish Medicines Consortium and by NHS England for defined patient groups taking
into account cost-effectiveness data available at the time of the technology appraisal.

Tocilizumab has only been approved for weekly subcutaneous use, although it has also been

studied in intravenous formulation(88). In the multicentre RCT (94) one of the treatment

arms received subcutaneous tocilizumab every 2 weeks, rather than weekly; patients in this

treatment arm also reached the primary endpoint, although it appeared to be less

efficacious in relapsing patients. The trials in GCA have not demonstrated an increased risk

of adverse events with tocilizumab(88, 94); pooling of data from both trials indicated a lower rate of serious adverse events in patients treated with tocilizumab than those treated with placebo (RR 0.64, 95% CI 0.41 to 1.00, QoE+++).

Abatacept was studied in a single, small trial(108). All patients received abatacept initially in addition to glucocorticoid therapy. Those achieving remission were randomized in week 12 to either continue the drug or to switch to placebo. Time-to-relapse analysis, which was the primary endpoint, significantly favoured abatacept. A post-hoc analysis to compare the proportion of patients in remission at 12 months did not show a significant difference between the treatment arms (RR 1.50 CI 0.71 - 3.17, QoE++), likely due to the small size of the study. At present abatacept is not approved for treatment of GCA.

TNF inhibitors have been studied in two randomised controlled trials(109, 110), both of which showed inefficacy but an increased incidence of infections. A third, small RCT of etanercept for GCA (111) did not fulfil the inclusion criteria for the literature review; although it showed a lower cumulative glucocorticoid dose in the etanercept arm, this trial failed to show a significant result for its primary outcome. Based on this evidence, TNF inhibitors cannot be recommended for GCA.

9. **Strong recommendation: Tocilizumab can be considered for GCA, in combination with a glucocorticoid taper, especially in patients at high risk of glucocorticoid toxicity or who relapse. TNF inhibitors are not recommended in GCA. QoE: +++ Consensus score: 9.61.**

Should anticoagulant or antiplatelet agents be given for GCA? (PICO 12-15)

No RCTs relating to aspirin or other anticoagulant/antiplatelet agents were found. A Cochrane review found no evidence from RCTs to determine the safety and efficacy of low-dose aspirin as an adjunctive treatment in GCA(112). National and society guidelines for the secondary prevention of coronary and other atherosclerotic vascular diseases should be followed.

10. **The routine use of antiplatelet or anticoagulant agents for GCA is not recommended. QoE: insufficient evidence. Consensus score: 9.28**

Should cholesterol-lowering agents be given for GCA? (PICO 16)

No RCTs of cholesterol-lowering agents for GCA were found. National and society guidelines for the secondary prevention of coronary and other atherosclerotic vascular diseases should be followed.

11. The routine use of cholesterol-lowering agents such as statins for GCA is not recommended. QoE: insufficient evidence. Consensus score: 9.53

Applicability and Utility

This guideline represents a framework upon which clinical practice should be based. However, as with any guideline, individual patient circumstances can have important influences on clinical decision-making, and clinicians should continue to work alongside patients to make shared decisions about care. Failure to adhere to this guideline should not necessarily be considered negligent, nor should adherence to these recommendations constitute a defence against a claim of negligence.

Potential organizational barriers to implementation

In practice, constraints of the healthcare system may create challenges to widespread implementation of this guideline. For example, implementing rapid-access vascular ultrasound as a diagnostic test in GCA is dependent not only on local expertise and experience in the technique itself, but also on the entire care pathway for patients with suspected GCA including appropriate, timely referrals and clinical expertise such that the results of the test can be interpreted appropriately.

As another example, follow up every 2-8 weeks for the first six months (less frequently thereafter), may seem ambitious but this could be delivered via a shared care model in collaboration with primary care, by which the patient and general practitioner receives the information and support they need and has ready access to secondary care if need be. Nonetheless it is also recognized that specific quality standards are necessary to drive clinical improvement.

Cost and cost-effectiveness implications for implementation

A formal health economic evaluation was not conducted as part of the guideline development process.

Use of additional imaging tests could incur healthcare costs. This has to be set against the advantages of accurate, timely diagnosis of GCA, in particular the potential cost savings of avoiding unnecessary treatment of patients without the disease.

A UK National Institute for Health and Care Excellence (NICE) technology appraisal has been conducted with regard to tocilizumab therapy for GCA(113), which has the potential to significantly increase the direct costs of drug treatment of GCA. Both biologic and non-biologic therapies used alongside glucocorticoid treatment would incur additional costs due to the requirements for regular blood monitoring. However, again this must be set against the potential cost savings arising from reduction in cumulative glucocorticoid doses and thereby a reduction in glucocorticoid-associated adverse events. On the basis of overall cost-effectiveness data, approval was granted by NHS England and the Scottish Medicines Consortium for tocilizumab treatment for defined GCA patient groups; readers are directed to the appropriate guidance for a fuller explanation.

Mechanism for auditing compliance with Guideline

Quality standards have been defined based on the fundamentals of good clinical care, as outlined in the General Principles. Audit should be performed on an unbiased (e.g. consecutive) sample of patients presenting to a clinic or service. A draft Audit Tool may be adapted for local use and will be available via the BSR Website.

39

Acknowledgements, Authors and Affiliations

GUIDELINE WORKING GROUP

Co-Chairs:

Bhaskar Dasgupta, Rheumatologist, Southend University Hospital, Southend, UK; (Bhaskar.Dasgupta@southend.nhs.uk)

Sarah Mackie, Associate professor and honorary consultant rheumatologist, University of Leeds and Leeds Teaching Hospital NHS Trust, Leeds, UK (s.l.mackie@leeds.ac.uk)

Guideline Working Group

Bhaskar Dasgupta, Rheumatologist, Southend University Hospital, Southend, UK; (Bhaskar.Dasgupta@southend.nhs.uk)

Eric L. Matteson, Rheumatologist and Epidemiologist, Mayo Clinic College of Medicine and Science, Rochester, MN, USA; (matteson.eric@mayo.edu)

Christian Dejaco, Rheumatologist, Medical University Graz, Austria, and Southend University Hospital, Southend, UK; (christian.dejado@gmx.net)

Sarah Mackie, Rheumatologist, University of Leeds, Leeds, UK; (S.L.Mackie@leeds.ac.uk)

Peter Lanyon, Rheumatologist, Nottingham University Hospitals, UK (Peter.Lanyon@nuh.uk)

Richard Watts, Rheumatologist, Ipswich Hospital, UK (richard.watts@ipswichhospital.nhs.uk)

Justin C. Mason, Rheumatologist, Imperial College London, UK (Justin.mason@imperial.ac.uk)

Chetan Mukhtyar, Rheumatologist, Norfolk and Norwich University Hospitals NHS Foundation Trust, UK (CHETAN.MUKHTYAR@nnuh.nhs.uk)

Raashid Luqmani, Rheumatologist, University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, UK (Raashid.Luqmani@ndorms.ac.uk])

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Marwan Bukhari, Rheumatologist ,University Hospitals of Morecambe Bay NHS Foundation

Trust (Marwan.Bukhari@mbht.nhs.uk])

Christian Mallen, General Practitioner and Professor of Primary Care, Keele University, UK

(c.d.mallen@keele.ac.uk)

Madeline Whitlock, Rheumatology Nurse Specialist, Southend University Hospital,
Southend, UK (madeline.whitlock@southend.nhs.uk)

Eoin O'Sullivan, Ophthalmologist, King's College Hospital, London, UK

(eoin.o'sullivan@nhs.net])

Susan Mollan, Ophthalmologist, Birmingham (soozmollan@doctors.org.uk])

Dorothy Byrne, patient, PMRGCAuk (DByrne@Channel4.co.uk)

Lorna Neill, patient, PMR-GCA Scotland (gdneill@gotadsl.co.uk)

Kate Gilbert, patient, PMRGCAuk (kate@pmrgcauk.com)

Maria Cid, Specialist in Internal Medicine, Hospital Clinic Provincial, Barcelona, Spain

(mccid@clinic.ub.es)

Frank Buttgereit, Rheumatologist, Charité University Medicine, Berlin, Germany

(frank.buttgereit@charite.de)

Elisebeth Brouwer, Rheumatologist, Groningen, Netherlands (e.brouwer@umcg.nl)

Alexandre Wagner Silva de Souza, Universidade Federal de São Paulo, Brazil

(alexandre_wagner@uol.com.br)

Haner Direskeneli, Rheumatologist, Istanbul, Turkey (hanerdireskeneli@gmail.com)

Marco Cimmino, Rheumatologist, Genova, Italy (cimmino@unige,it)

Alfred Mahr, Rheumatologist, Paris, France (alfred.mahr@aphp.fr)

Peter A. Merkel, Rheumatologist, University of Pennsylvania, Philadelphia, PA, USA

(pmerkel@upenn.edu)

Tanaz A. Kermani, Rheumatologist, University of California, Los Angeles, USA

(TKermani@mednet.ucla.edu)

Wolfgang Schmidt, Rheumatologist, Berlin-Buchs, Germany (Schmidt.wa@t-online.de)

41

Asad Khan, University Hospitals Birmingham, Birmingham, UK (asad.khan@heartofengland.nhs.uk)

Dario Camellino, Rheumatology Fellow, Genoa, Italy (Dario.camel@gmail.com)

Maria Sandovici, Rheumatologist, Groningen, Netherlands (m.sandovici01@umcg.nl)

Christina Duftner, Rheumatologist, Innsbruck, Austria (christina.duftner@gmx.at)

Solange Gonzalez-Chiappe, Rheumatologist, Paris (solange.gonzalez-chiappe@aphp.fr)

Simone Appenzeller, Rheumatologist, Sao Paolo, Brazil (appenzellersimone@yahoo.com)

Elaine Yaceshyn, Rheumatologist, Edmonton, Canada (eyacyshyn@ualberta.ca)

Steven Ytterberg, Rheumatologist, Mayo Clinic College of Medicine and Science, Rochester, USA (ytterberg.steven@mayo.edu)

Gary Reynolds, Rheumatologist, Newcastle University, Newcastle-upon-Tyne, UK (gary.reynolds@newcastle.ac.uk)

Statement of contribution of the literature review team

Christian Dejaco led the SLR team. The literature review team was split into 3 groups, each group consisting of 3 members: Group 1 (Duftner, Mackie, Appenzeller) performed the SLR on diagnostic tests/strategies, group 2 (Dejaco, Camellino, Hutchings) performed the SLR on therapeutic interventions and group 3 (Mahr, Gonzalez-Chiappe, Wagner de Souza) performed the SLR on prognostic factors. Two members of each group independently performed screening, inclusion/exclusion of articles, data extraction and quality appraisal. Results were compared between the two members and any discordance was resolved by discussion, consulting the third member of the group where no consensus could be reached. CD supervised the progress of the SLR in each group and the preparation of the evidence tables. The searches underpinning the 2018 update to the systematic literature review were conducted by Gary Reynolds, who also worked with the literature review team in the appraisal of the new evidence.

Individuals who contributed to the guideline development but did not participate in the final voting are listed, and their contributions gratefully acknowledged, below:

Niral Karia, Ophthalmologist, Southend University Hospital, UK

Kevin Barraclough, General Practitioner, Hoyland House General Practice, Painswick, UK (k.barraclough@btinternet.com)

Eric Clark, patient (Ericclark@clarkwrite.com)

Mavis Smith, patient (PMR and GCA North East) (mavis@eastcliff.org.uk)

Andrew Hutchings, Statistician, London School of Hygiene & Tropical Medicine, UK; (Andrew.Hutchings@lshtm.ac.uk)

Presentation and dissemination of final guidelines

The final guidelines will be disseminated by publication in the journal Rheumatology (Oxford) as well as by uploading on to the BSR homepage.

Disclosures and conflicts of interest

Frank Buttgereit - Frank Buttgereit reports receiving consultancy fees, honoraria and/or travel

expenses from Horizon Pharma, Mundipharma, Roche and Pfizer, and grant/study support

from Horizon Pharma and Mundipharma.

Haner Direskeneli - Local Advisory Board Member for Roche for GCA.

Tanaz A. Kermani - Consultancy for Abbvie March 2018. 1.5 hours total, amount $525.

Wolfgang Andreas Schmidt - Consulting fees: GlaxoSmithKline, Novartis, Roche, Sanofi

Speaker's bureau: Chugai, GlaxoSmithKline, Novartis, Roche, Sanofi.

Justin Mason - I have received speaker fees and consultancy fees from Roche/Chugai.

Susan Mollan - Roche (Advisory boards 2016, 2017) Roche speaker fees (2016, 2017, 2018,

2019) Chugai-Roche Ltd speaker fees (2018, 2019).

Dario Camellino - Travel expenses, consultancy and speaker fees from AbbVie, Celgene,

Janssen-Cilag, Lilly, Mylan, Sanofi. None of them was related to this project.

Bhaskar Dasgupta - Paid consultancies for membership of Clinical Trials Advisory Boards,

for developing trials protocols as well as speaker fees from Roche-Chugai, Sanofi, ERT,
BMS, GSK,Abbvie as well as Ultrasound workshop/GCA symposium grants to Southend

university Hospital.

Marwan Bukhari - I have been involved in the GCA consortium, which is indirectly funded

by Roche/ chugai. I have also been involved in a virtual advisory board by Roche

pharmaceuticals about managing GCA.

Disclosures:

Sarah Mackie - I am Patron of PMRGCAuk which is a patient support group (not to my

knowledge in receipt of funding from industry) that also undertakes advocacy.   I am

employed by the University of Leeds as an academic rheumatologist and as required for my

role I have published various academic publications on GCA. I am also a founder member of
the TARGET Research Consortium https://lida.leeds.ac.uk/target-2/about-us/ which is a

partnership between academics, industry and clinicians.   I am co-chair of the OMERACT

PMR Working Group and a member of the OMERACT Vasculitis Working Group which

includes large vessel vasculitis as part of its remit.   I am also encouraged to carry out public
engagement roles and I speak sometimes to patient support groups. I was interviewed by a

journalist on behalf of a US patient support group called creakyjoints.org and was quoted in

the online article but I avoided being quoted on any specific therapy

https://creakyjoints.org/education/giant-cell-arteritis/   I was sub-investigator at my hospital

for the licensing RCT of tocilizumab for giant cell arteritis (GiACTA), site PI and for

sirukumab for giant cell arteritis (SIRRESTA) I am local principal investigator and UK CI

(for purposes of IRAS) for an international multicentre industry sponsored trial of sarilumab for GCA.

Asad Khan - I have co-authored a review entitled "Imaging in Giant Cell Arteritis" (DOI

10.1007/s11926-015-0527-y). This review is related to the likely contents of the guideline but

did not form part of the evidence base for it.

Christian Dejaco - First author of EULAR imaging recommendations in large vessel

vasculitils First author of ACR/EULAR recommendations for management of PMR

Coauthor of management recommendations for Large vessel vasculitis.

Lorna Murray Neill - Current Chair of PMR-GCA Scotland.

Peter A. Merkel - Research Support: Bristol-Myers Squibb, Genentech/Roche.

Maria Cid - In the last year I have participated in clinical trials sponsored by GSK, and

Kiniksa   I have participated as co-author in publications of work sponsored by Roche.

Kate Gilbert - I am a representative of PMRGCAuk, the national charity for patients with

polymyalgia rheumatica and giant cell arteritis, and my involvement with this guideline

enhances the public profile of the charity.

Dorothy Byrne - Vice Chair of PMRGCAuk.

Elisabeth Brouwer - Presently I perform cohort research in GCA as an employee of the

UMCG in the Netherlands. Part of the work is funded by Reuma Nederland. I also lead/ am

involved in the development of the local and national guidelines for GCA in the Netherlands..

Elaine A. Yacyshyn - Associate Professor Rheumatology at University of Alberta i) I have

been asked to speak at an educational event sponsored by a pharmaceutical company which is

related to my area of expertise. Action: Wrote my own slides, did not accept financial payment which went to Institution.

Wolfgang Andreas Schmidt - Participation in trials / studies: GlaxoSmithKline, Novartis,

Roche, Sanofi.

Eric Matteson - Task force participation: EULAR 2018 standardized core set of data to be

collected in giant cell arteritis registries and databases.

Justin Mason - I am Professor of Rheumatology at Imperial College London and Head of the

Cardiovascular Division.

Susan P Mollan - I was the representative from the Royal College of Ophthalmologists for

this guideline. I was part of the EULAR GCA guideline group. I am part of the European

Headache Federation GCA guideline group.   I was author of the Cochrane review in recommending utility of Aspirin in GCA.

Lorna Neill - Chair of PMR-GCA Scotland Patient representative on EULAR working group on Imaging in LVV.

Bhaskar Dasgupta - I am the Honorary President of PMRGCAuk , a patient support charity I was investigator for GiACTA, co-author of the NEJM article that led to approval of tocilizumab for GCA, and led the BSR response to NICE that facilitated NICE approval of tocilizumab for relapsing/refractory GCA I was the subject of the BBC2 Health program 'Trust me, I'm a doctor' made on GCA and released Feb 2017 I have authored over 200 artcles on GCA,PMR and was the first author of the original BSR guidance on GCA as well PMR (including the EULAR ACR guidance on PMR).

Peter Lanyon - I was President of the BSR April 2016-18. I currently chair the Rare Autoimmune Rheumatic Disease Alliance.

Table 1. A proposed list of clinical assessments that could be carried out at or near diagnosis of giant cell arteritis (GCA).

History and examination	Investigations
• Height and weight • Features of giant cell arteritis relevant to prognosis: fever, sweats, or weight loss; ischaemic manifestations (jaw claudication, tongue claudication) • Signs and symptoms indicating involvement of extracranial arteries e.g. bruits, different blood pressures in the two arms, limb claudication • Ophthalmological evaluation for patients with transient or permanent visual loss or diplopia • History of comorbidities and medications that might predispose to glucocorticoid-related adverse effects:	• Measures of activity of GCA: laboratory markers of inflammation (CRP for all patients, plus either ESR or plasma viscosity), and full blood count (platelet count may be elevated in GCA). • Consider serum protein electrophoresis and urine Bence-Jones protein/serum free light chains if ESR raised out of proportion to CRP • Baseline laboratory tests of major organ system function (plasma glucose, renal and liver function

infection, hypertension, diabetes, osteoporosis, low-trauma fracture, dyslipidaemia, peptic ulcer, psychiatric adverse effects • Features that may suggest alternative diagnosis, e.g.: neurological deficits, very severe constitutional symptoms, or localised ear, nose and throat signs	tests, calcium and alkaline phosphatase) • Screening tests for risk of serious infection* (may include urine dipstick, chest radiograph, tests for latent tuberculosis according to local or national protocol) • Screening tests for osteoporosis risk* (may include TSH, vitamin D, bone density test) (DXA)

*Screening tests for infection and osteoporosis to be considered in light of relevant local and national guidelines. Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; TSH, thyroid stimulating hormone; DXA, dual-energy x-ray absorptiometry.

Table 2. A typical glucocorticoid tapering schedule for giant cell arteritis.

This is an example of a typical glucocorticoid taper schedule, based on that described in the 2010 BSR guidelines for GCA(114) and similar to the control arm of a recent GCA clinical trial(94). High-quality evidence comparing different glucocorticoid taper schedules in GCA is not available. Alternative approaches include, for example, reducing prednisolone by 10mg/week in patients who are in remission above 20mg daily, and/or reducing the dose slower than stated here in patients who are on or below 5mg daily. In all cases taper schedules should be individualised based on the patient. For relapse management, see Table 3.

Daily prednisolone dose	Example rate of reduction in daily prednisolone dose	Notes
40-60mg oral prednisolone: initial dose	Continue at same dose until GCA symptoms and	Purpose: induction of clinical remission

|		
for patients with active GCA	acute phase markers resolve	
In clinical remission, and above 20mg prednisolone	Reduce daily dose by 10mg every 2 weeks	Aim to reach 20mg prednisolone once the patient has been in remission for 4-8 weeks. If symptoms suggestive of GCA relapse occur during taper, consult Table 3
In clinical remission, above 10mg prednisolone but less than 20mg	Reduce daily dose by 2.5mg every 2-4 weeks	
In clinical remission, and on 10mg prednisolone or less	Reduce daily dose by 1mg every 1-2 months	

Table 3. Examples of symptoms that may signify relapse of GCA during glucocorticoid taper that require further evaluation and, if judged to be due to GCA relapse, escalation of glucocorticoid treatment.

This table outlines how new symptoms in GCA patients, in the absence of other risk factors or significant co-morbidities, may influence management decisions. New visual loss or diplopia should be urgently evaluated by an ophthalmologist. Acute phase markers should be measured and, if found to be elevated, may increase the clinical suspicion of GCA relapse. At present, the only agents with any evidence for glucocorticoid-sparing in GCA are methotrexate and tocilizumab.

Symptom	Possible significance in a patient with GCA	Action to consider if symptom is judged to be due to GCA relapse
Return of headache symptoms	Possible GCA relapse without ischaemic manifestations	Return to previous higher prednisolone dose

Jaw or tongue claudication	Possible GCA relapse with ischaemic manifestations	Consider high-dose oral prednisolone (40-60mg) with or without glucocorticoid-sparing agent
Weight loss, fever, night sweats, anaemia, persistent acute phase response, new/recurrent PMR symptoms, limb claudication, abdominal pain or back pain	Possible GCA-related inflammation of the aorta and/or its proximal branches	Investigate with vascular imaging (MRI, CT or FDG-PET-CT); consider increasing oral prednisolone and/or adding glucocorticoid-sparing agent

Figure 1. A possible approach to using rapid-access vascular ultrasound to assist in clinical diagnostic decision-making in suspected cranial GCA.

Estimate probability of GCA from symptoms, signs and laboratory tests

Low (<20%)

Medium (20-50%), *or* ultrasound result is equivocal

High (>50%)

Ultrasound negative

Ultrasound positive

Ultrasound negative

Ultrasound positive

Temporal artery biopsy

Biopsy negative

Biopsy positive

Consider alternative diagnoses

Re-assess probability of GCA

Continue to treat as GCA

This figure illustrates a possible approach to using rapid-access vascular ultrasound, if available, in suspected GCA. Estimation of probability of GCA is based on all information available (symptoms, signs, laboratory tests, and alternative non-GCA explanations for the clinical picture) and can be updated based on new information (clinical course, result of temporal and axillary ultrasound and/or result of temporal artery biopsy). This assessment is based on clinical judgement and should ideally be performed by an individual with specialist expertise. Note that for a medium (20-50%) estimated probability of GCA, it may be useful to perform an ultrasound prior to biopsy, in case the biopsy is negative. For a high clinical probability of GCA, a positive ultrasound alone may be sufficient, as illustrated here; however, in these cases it is still acceptable to perform biopsy in addition to ultrasound in order to further increase diagnostic certainty. In the absence of clinical features of cranial GCA, temporal artery biopsy can still be positive, but imaging of the extracranial large vessels may be considered instead of, or in addition to, temporal artery biopsy. Recently various clinical prediction rules have been proposed to assist clinicians in the estimation of

probability of GCA; the performance of a clinical prediction rule developed in another

setting should ideally be checked using local audit data prior to adopting into local clinical

practice. If rapid-access vascular ultrasound is not available, patients treated for suspected

GCA should all have a temporal artery biopsy. None of these tests should delay the

prescribing of high-dose glucocorticoid therapy for patients with strongly suspected GCA.

Appendix A. List of abbreviations

AE	Adverse event
ANCA	Anti-neutrophil cytoplasmic antibodies
BSR	British Society for Rheumatology
CI	Confidence interval
CRP	C-reactive protein
CT	Computed tomography
CTA	Computed tomography angiography
DB-RCT	Double-blinded randomised controlled trial
ESR	Erythrocyte sedimentation rate
FDG	18F-Fluorodeoxyglucose
GCA	Giant cell arteritis
GP	General practitioner
GRADE	Grading of Recommendations, Assessment, Development, and Evaluation
ISRCTN	International Standard Randomised Controlled Trial Number Register
LR	Likelihood ratio
MRI	Magnetic resonance imaging
NSAIDS	Non-steroidal anti-inflammatory drugs
PET	Positron emission tomography
PMR	Polymyalgia rheumatica
QUIPS	Quality In Prognosis Studies
QoE	Quality of Evidence
RCT	Randomised controlled trial
SBU	Swedish Council on Technology Assessment in Health Care

51

SLR	Systematic literature review
TNFi	Tumor necrosis factor-alpha inhibitor
USS	Ultrasound scan

Appendix B. List of critical outcome parameters, adapted from the PMR guidelines project and further modified by a survey conducted for this guidelines project

- Sight loss and other ischaemic complications
- Disease remission
- Disease relapse
- Duration of glucocorticoid therapy
- Discontinuation of glucocorticoid therapy
- Glucocorticoid side effects
- Other therapy related side effects
- Response to glucocorticoid therapy
- Cumulative glucocorticoid dose
- Inflammatory markers (i.e. ESR, CRP)
- Patients assessment of global wellbeing (VAS – Visual analogue score)
- Severity (VAS) / duration (minutes) of morning stiffness
- Lowest possible glucocorticoid dose (Prednisolone less than 5mg/day)
- Functional status (HAQ or other measures)
- Quality of life (SF-36, EQ5D etc.)
- Cardiovascular events (MI,strokes,PVD)
- Mortality
- Hospitalization (due to disease, its complications, co-morbidity and/or treatment related complications)
- Impact on patients' social environment
- Fatigue
- Imaging of shoulder/hip
- Healthcare resource use (health economics)
- Disease activity score

Appendix C. List of questions structured in PICO format (Patients, Intervention, Comparator, Outcome)

Diagnostic imaging PICOs:

Should ultrasound (I) be used for the diagnosis of GCA (O) in patients with suspected GCA (P), using clinical diagnosis or temporal artery biopsy as reference standard (C)?

Investigation of sources of heterogeneity:

(P): the target population may be defined by different criteria including new onset headache, polymyalgic syndrome and/or unexplained constitutional symptoms.

(I): Duplex ultrasound of temporal and/or extracranial arteries with different ultrasound pathologies including the halo sign, compression sign, stenosis, occlusion.

(C): clinical diagnosis (without formal criteria), ACR classification criteria and temporal artery biopsy result; GCA with/without extra-cranial manifestations.

PICO questions in a similar format were used for MRI and FDG-PET.

Intervention PICOs:

Initial oral glucocorticoid dose

1. In GCA (P), what is the effect of oral glucocorticoids at doses <40 mg/day prednisone equivalent) (I) on outcome (O) compared with doses between 40 and 60 mg/day prednisone equivalent (C)?

2. In GCA (P), what is the effect of oral glucocorticoids at doses 40-60 mg/day prednisone equivalent (I) on outcome (O) compared with doses >60 but ≤ 100 mg/day of prednisone equivalent (C)?

3. In GCA (P) what is the effect of oral glucocorticoids at doses of 0.5 mg/kg/day prednisone equivalent (i) on outcome (O) compared with doses of 1 mg/kg/day (C)?

4. In GCA (P), what is the effect of intravenous methylprednisolone pulse therapy (>100mg and ≤1000mg per day over 3 consecutive day) plus oral glucocorticoids (I) on outcome (O) compared with oral glucocorticoids alone (C)?

Glucocorticoid schedule

5. In GCA (P), what is the effect of rapid taper of glucocorticoids (I) on outcome (O) compared with slow taper of glucocorticoids (C)?

Divided versus single dosage of oral glucocorticoids

6. In GCA (P), what is the effect of administration of oral glucocorticoid therapy at divided doses (morning plus evening) (I) on outcome (O) compared with single dose (morning only) (C)?

7. In GCA (P), what is the effect of administration of oral glucocorticoid therapy as alternate day doses (I) on outcome (O) compared with single dose (C)?

Modified release glucocorticoid preparations

8. In GCA (P), what is the effect of treatment with oral modified-release prednisolone (I) on outcome (O) compared with standard prednisolone at equivalent dose (C)?

Role of non-biologic disease modifying anti-rheumatic drugs

9. In GCA (P), what is the effect of glucocorticoids plus methotrexate (I) on outcome (O) compared with glucocorticoids alone (C)?

10. In GCA (P), what is the effect of glucocorticoids plus non-biological disease modifying anti-rheumatic drugs (non-methotrexate DMARDs) (I) on outcome (O) compared with glucocorticoids alone (C)?

Role of biological disease modifying anti-rheumatic drugs

11. In GCA (P), what is the effect of glucocorticoids plus biological agents (I) on outcome (O) compared with glucocorticoids alone (C)?

Role of aspirin and anticoagulants

12. In GCA (P), what is the effect of aspirin plus glucocorticoids (I) on outcome (O) compared with glucocorticoids alone (C)?

13. In GCA (P), what is the effect of (standard or low molecular weight) heparin plus

glucocorticoids (I) on outcome (O) compared with glucocorticoids alone (C)?

14. In GCA (P), what is the effect of warfarin plus glucocorticoids (I) on outcome (O)

compared with glucocorticoids alone (C)?

15. In GCA (P), what is the effect of new oral anticoagulants (NOACs) plus glucocorticoids
(I) on outcome (O) compared with glucocorticoids alone (C)?

Role of Statins

16. In GCA (P), what is the effect of statins plus glucocorticoids (I) on outcome (O)

compared with glucocorticoids alone (C)?

Role of non-pharmacological therapy

17. In GCA (P), what is the effect of glucocorticoids plus exercise programme (I) on
outcome (O) compared with glucocorticoids alone (C)?

PICO questions on risk factors (prognostic factors):

1. In GCA (P), what is the effect of older age at diagnosis (I) on outcome (O) compared

with younger age (C)?

2. In GCA (P), what is the effect of female sex (I) on outcome (O) compared with male

sex (C)?

3. In GCA (P), what is the effect of high levels of inflammatory markers, erythrocyte

sedimentation rate (ESR) and/or C-reactive protein (CRP), at diagnosis (I) on

outcome (O) compared with low levels of inflammatory markers (C)?

4. In GCA (P), what is the effect of more active/severe disease at diagnosis (I) on

outcome (O) compared with lower disease activity/severity (C)?

5. In GCA (P), what is the effect of rapid response to glucocorticoids (I) on outcome (O)

compared with delayed response (C)?

6. In GCA (P), what is the effect of positive TAB histology (I) on outcome (O) compared

with negative TAB histology (C)?

To avoid prematurely imposing cut-points and risking loss of important information, the group decided not to define cut-points for the following prognostic factor categories at this stage of the SLR: "rapid/slow taper of glucocorticoid therapy" "older/younger age",

"high/low levels of inflammatory markers", "more/less active/severe disease",

"longer/shorter symptom duration".

Appendix D. Search strategies (shown for MEDLNE only, similar strategies were used for the other databases)

Search strategy for diagnostic studies

Key words for (Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 to Present; Ovid MEDLINE(R) Daily Update):

Exp, explode; *, truncation; /, Mesh term; mp, keyword; ADJ, adjacent

1.   exp Giant Cell Arteritis/

2.   (temporal ADJ2 arteritis).mp.

3.   (giant ADJ2 cell ADJ2 arteritis).mp.

4.   Horton.mp

5.   GCA.mp

6.   Exp Aortitis/

7.   large vessel vasculitis.mp

8.   large vessel arteritis.mp

9.   polymyalgia arteritica.mp.

10.   single organ arteritis.mp

11.   single organ vasculitis.mp

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

12.   OR/1-11

13.   sensitiv*.mp

14.   specific*.mp

15.   reliab*.mp

16.   positiv*.mp

17.   negativ*.mp

18.   diagnos*.mp

19.   detect*.mp

20.   di.fs

21.   predict*.mp

22.   accura*.mp

23.   (observer adj variation*).mp

24.   (roc adj curve*).mp

25.   (likelihood adj3 ratio*).mp

26.   likelihood function/

27.   OR/13-26

28.   exp Ultrasonography/

29.   ultrasound.mp

30.   ultrasonograph*.mp.

31.   sonograp*.mp.

32.   (Colour ADJ2 Doppler).mp

33.   OR/28-32

34.   12 AND 27 AND 33

35.   Exp Magnetic Resonance Imaging/

36.   MR imag*.mp.

37.   MRI.mp

38.   magnetic resonance imag*.mp

39.   OR/35-38

40.   12 AND 27 AND 39

41.   exp Positron Emission Tomography/

42.   Exp tomography, emission-computed/

43.   (Positron ADJ2 Emission ADJ2 Tomography).mp

44.   Pet.mp

45.   pet*.mp

46.   petscan*.mp

47.   emission.mp AND tomograph.mp

48.   Tomographs.mp

49.   tomographic*.mp

50.   tomography.mpt

51.   tomographies.mp

52.   OR/41-51

53.   12 AND 27 AND 52

54.   34 OR 40 OR 53

Limit: English language

Search strategy for interventional trials

Key words for (Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 to Present; Ovid MEDLINE(R) Daily Update):

Exp, explode; *, truncation; /, Mesh term; mp, keyword; ADJ, adjacent

1. exp Giant Cell Arteritis/

2. (temporal ADJ2 arteritis).mp.

3. (giant ADJ2 cell ADJ2 arteritis).mp.

4. Horton.mp

5. GCA.mp

6. Exp Aortitis/

7. large vessel vasculitis.mp

8. large vessel arteritis.mp

9. polymyalgia arteritica.mp.

10. single organ arteritis.mp

11. single organ vasculitis.mp

12. OR/1-11

13. Exp Clinical Trial/

14. randomized controlled trial.pt.

15. controlled clinical trial.pt

16. random*.mp

17. placebo.mp

18. trial.mp

19. OR/13-18

20. 12 AND 19

Limit: English language

Search strategy for prognostic studies

Key words for (Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid

MEDLINE(R) 1946 to Present; Ovid MEDLINE(R) Daily Update):

Exp, explode; *, truncation; /, Mesh term; mp, keyword; ADJ, adjacent

1. exp Giant Cell Arteritis/

2. (temporal ADJ2 arteritis).mp.

3. (giant ADJ2 cell ADJ2 arteritis).mp.

4. Horton.mp

5. GCA.mp

6. Exp Aortitis/

7. large vessel vasculitis.mp

8. large vessel arteritis.mp

9. polymyalgia arteritica.mp.

10. single organ arteritis.mp

11. single organ vasculitis.mp

12. OR/1-11

13. Prognos*.mp

14. Predict*.mp

15. Course*.mp

16. follow-up stud*.mp

17. case-control stud*.mp

18. cohort stud*.mp

19. comparative stud*.mp

20. longitudinal stud*.mp

21. program evaluation.mp

1
2
3   22.   prospective stud*.mp

4
5
6   23.   treatment outcome.mp

7
8   24.   risk factor*.mp

9
10   25.   OR/13-24

11
12
13   26.   12 AND 25

14
15   Limit: English language

16
17
18
19
20   **Appendix E. Likelihood ratios for various imaging tests for GCA**
21   These likelihood ratios (LRs) are calculated from the diagnostic studies reported in the main text; LRs

22
23   are another way of presenting sensitivity and specificity (diagnostic accuracy) data. Random-effects
24
25   meta-analysis was used to generate pooled LRs. A LR of 1.0 indicates a useless test; a LR of 2.0 would
26   double the odds that the disease is present, whereas a LR of 0.5 would halve the odds that the disease
27
28   is present. For comparison, a positive temporal artery biopsy would have an estimated LR of 98, and
29
30   a negative biopsy would have a LR of 0.61, in relation to clinical diagnosis of GCA (data extracted from
31   TABUL study (19); similar likelihood ratios for biopsy vs clinical diagnosis were reported in another
32
33   study (75)).
34

Index test	Reference standard	Number of studies	Pooled positive likelihood ratio (95% CI)	Pooled negative likelihood ratio (95% CI)
Ultrasound: halo, stenosis or occlusion	Clinical diagnosis of GCA	3	6.2 (2.2 – 17)	0.22 (0.059 – 0.84)
Ultrasound: halo, stenosis or occlusion	Temporal artery biopsy	4	5.5 (2.1 – 14)	0.18 (0.074 – 0.42)
MRI cranial arteries	Clinical diagnosis of GCA	6	5.7 (3.6 – 9.2)	0.29 (0.20 – 0.41)
MRI cranial arteries	Temporal artery biopsy	5	3.7 (2.4 – 5.9)	0.08 (0.045 – 0.15)

FDG-PET of large vessels	Clinical diagnosis of GCA	1	13 (0.86 – 200)	0.36 (0.18-0.72)
FDG-PET of thoracic vessels	Temporal artery biopsy	1	3.8 (1.7 – 8.5)	0.54 (0.30 – 0.98)
CT angiography	Clinical diagnosis of GCA	1	3.3 (0.94 – 12)	0.34 (0.14 – 0.85)

Appendix F. An example of a care pathway for suspected GCA, called the fast-track pathway

This is an example of a care pathway for suspected GCA that was implemented at one hospital, Southend University Hospital NHS Foundation Trust, UK. This care pathway, which was called the "fast track pathway", was awarded a 2016 BSR Case Study for Outstanding Best Practice. It has since been adapted by some other hospitals in the UK and elsewhere.

Other hospitals have developed different care pathways depending on their local circumstances. Audit will facilitate adherence to quality standards.

Appendix G. Research agenda

The group agreed that future clinical trials in GCA should be well-designed and properly powered. A core outcome set for future GCA clinical trials would ensure that outcomes of importance to all stakeholder groups are included in all GCA trials; as well as facilitating regulatory approvals this would also be beneficial for future evidence synthesis. A recent editorial outlines some of the following research areas in more detail (115).

Specific research questions:

1.   How could we improve methods for diagnosis of GCA (including imaging, biomarkers and clinical algorithms, as well as organizational changes to care pathways)? Are clinical prediction scores that estimate the probability of GCA using clinical and laboratory features useful in the setting of suspected GCA?

2. What outcome measures, including patient-reported outcomes, response-, remission- and relapse-criteria, imaging outcomes, and composite outcome measure scores, should be used in GCA clinical trials and in clinical practice?

3. What is the efficacy and safety of different routes of glucocorticoid administration (oral, intramuscular, intraarticular), different initial glucocorticoid doses, different glucocorticoid tapering regimens, and different glucocorticoid flare doses? In particular, does high-dose oral prednisolone differ in efficacy and safety from intravenous methylprednisolone?

4.   What is the efficacy and safety of additional therapies, both non-TNF biologic and other novel therapies, and oral DMARDs such as methotrexate, leflunomide, azathioprine and mycophenolate? What is the optimal strategy to use additional therapies in GCA: monotherapy versus combination therapy, early versus late introduction and (particularly for biologics) use of them with or without glucocorticoids?

5.   What can we learn from post-marketing studies of tocilizumab, including registries and observational studies, about its optimal use, including effectiveness and safety?

6.	What is the minimal/optimal duration of glucocorticoid therapy? In patients who

need additional therapy (either non-biologic DMARD, or biologic) how long should this

additional therapy be given and how should we manage patients who need to stop

additional therapies?

7.	Is aspirin beneficial for patients with GCA, in those patients for whom aspirin is not
already indicated for other reasons?

8.	What is the optimal strategy for shared primary and specialty care? How can

patients better be involved in treatment decisions? Can we develop decision aid tools to

help doctors and patients make more informed, shared decisions about management

options in GCA? What should self-management mean in GCA?

9.	What is the value of tight control (or "treat to target") versus conventional
management strategies in GCA?

10.	How should patients with long-standing GCA and long-term, low-dose glucocorticoid

therapy be managed?

11.	What are the health economic implications (cost-utility, cost-effectiveness) of

different ways of diagnosing and managing GCA?

12.	What is the value of non-pharmacological therapies in GCA? This includes exercise,
physiotherapy, diet, and nutritional supplements including fish oils.

13.	What imaging tests (including, but not limited to, ultrasound) may be useful for the

diagnosis and monitoring of GCA, including identification of overlap with other diseases (e.g.

PMR, large vessel vasculitis or inflammatory arthritis)?

14.	Which soluble and tissue biomarkers may be useful in the diagnosis and monitoring

of GCA?

15.	What factors are prognostic in GCA? Can we define prognostically-relevant

subgroups of GCA patients, and can we reach a better understanding of the mechanisms

underlying these prognostic factors? Should prognostic factors guide stratified care in GCA

(treatment strategies selected on the basis of the patient's prognostic subgroup)?

16.	Since drugs targeted to IL-6 pathways (eg tocilizumab) can suppress levels of CRP

and ESR, how should we monitor disease activity in GCA patients receiving treatment with
these drugs? Should imaging tests and/or alternative biomarkers be used to inform clinical

decisions?

17. What is the morbidity and mortality of GCA patients (with a particular focus on cardiovascular risk) in long-term observational studies?

18. What is the aetiopathogenesis of GCA? Which targeted therapies could be developed based on new knowledge of disease mechanisms?

References

1. Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990-2001. Annals of the rheumatic diseases. 2006;65(8):1093-8.
2. De Smit E, Palmer AJ, Hewitt AW. Projected worldwide disease burden from giant cell arteritis by 2050. J Rheumatol. 2015;42(1):119-25.
3. Weyand CM, Goronzy JJ. Pathogenic principles in giant cell arteritis. Int J Cardiol. 2000;75 Suppl 1:S9-S15; discussion S7-9.
4. Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology (Oxford). 2017;56(4):506-15.
5. Aiello PD, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG. Visual prognosis in giant cell arteritis. Ophthalmology. 1993;100(4):550-5.
6. Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, Martinez-Taboada VM, Delgado-Rodriguez M, Figueroa M, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998;41(8):1497-504.
7. Mackie SL, Dasgupta B, Hordon L, Gough A, Green M, Hollywood J, et al. Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors. Rheumatology (Oxford). 2011;50(11):2014-22.
8. Koster MJ, Matteson EL, Warrington KJ. Large-vessel giant cell arteritis: diagnosis, monitoring and management. Rheumatology (Oxford). 2018;57(suppl_2):ii32-ii42.
9. Kermani TA, Warrington KJ, Crowson CS, Ytterberg SR, Hunder GG, Gabriel SE, et al. Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Annals of the rheumatic diseases. 2013;72(12):1989-94.
10. Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):1594-7.
11. Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015;74(10):1799-807.
12. Dasgupta B, Borg FA, Hassan N, Barraclough K, Bourke B, Fulcher J, et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford). 2010;49(1):186-90.

13.	van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70(3):414-22.

14.	Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62(11):1515-26.

15.	Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64(4):395-400.

16.	Hsu J, Brozek JL, Terracciano L, Kreis J, Compalati E, Stein AT, et al. Application of GRADE: making evidence-based recommendations about diagnostic tests in clinical practice guidelines. Implement Sci. 2011;6:62.

17.	Iorio A, Spencer FA, Falavigna M, Alba C, Lang E, Burnand B, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ. 2015;350:h870.

18.	Sackett DL, Haynes RB. The architecture of diagnostic research. BMJ. 2002;324(7336):539-41.

19.	Luqmani R, Lee E, Singh S, Gillett M, Schmidt WA, Bradburn M, et al. The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health technology assessment (Winchester, England). 2016;20(90):1-238.

20.	Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401-6.

21.	Brozek JL, Akl EA, Jaeschke R, Lang DM, Bossuyt P, Glasziou P, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies. Allergy. 2009;64(8):1109-16.

22.	Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529-36.

23.	Guyatt GH, Schunemann HJ, Djulbegovic B, Akl EA. Guideline panels should not GRADE good practice statements. J Clin Epidemiol. 2015;68(5):597-600.

24.	Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66(7):719-25.

25.	Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372(9634):234-45.

26.	Smetana GW, Shmerling RH. Does this patient have temporal arteritis? Jama. 2002;287(1):92-101.

27.	Patil P, Williams M, Maw WW, Achilleos K, Elsideeg S, Dejaco C, et al. Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. Clin Exp Rheumatol. 2015;33(2 Suppl 89):S-103-6.

28.	Diamantopoulos AP, Haugeberg G, Lindland A, Myklebust G. The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology (Oxford). 2016;55(1):66-70.

29.   Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand. 2002;80(4):355-67.

30.   Vodopivec I, Rizzo JF, 3rd. Ophthalmic manifestations of giant cell arteritis. Rheumatology (Oxford, England). 2018;57(suppl_2):ii63-ii72.

31.   Liozon E, Dalmay F, Lalloue F, Gondran G, Bezanahary H, Fauchais AL, et al. Risk Factors for Permanent Visual Loss in Biopsy-proven Giant Cell Arteritis: A Study of 339 Patients. J Rheumatol. 2016;43(7):1393-9.

32.   Cid MC, Font C, Oristrell J, de la Sierra A, Coll-Vinent B, Lopez-Soto A, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis and rheumatism. 1998;41(1):26-32.

33.   Salvarani C, Della Bella C, Cimino L, Macchioni P, Formisano D, Bajocchi G, et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxford, England). 2009;48(3):250-3.

34.   Gonzalez-Gay MA, Pineiro A, Gomez-Gigirey A, Garcia-Porrua C, Pego-Reigosa R, Dierssen-Sotos T, et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine. 2004;83(6):342-7.

35.   Yates M, MacGregor AJ, Robson J, Craven A, Merkel PA, Luqmani RA, et al. The association of vascular risk factors with visual loss in giant cell arteritis. Rheumatology (Oxford). 2017;56(4):524-8.

36.   de Boysson H, Daumas A, Vautier M, Parienti JJ, Liozon E, Lambert M, et al. Large-vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549 patients. Autoimmunity reviews. 2018;17(4):391-8.

37.   Muratore F, Kermani TA, Crowson CS, Koster MJ, Matteson EL, Salvarani C, et al. Large-Vessel Dilatation in Giant Cell Arteritis: A Different Subset of Disease? Arthritis care & research. 2018;70(9):1406-11.

38.   Gonzalez-Gay MA, Garcia-Porrua C, Pineiro A, Pego-Reigosa R, Llorca J, Hunder GG. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine. 2004;83(6):335-41.

39.   Robson JC, Kiran A, Maskell J, Hutchings A, Arden N, Dasgupta B, et al. The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. Annals of the rheumatic diseases. 2015;74(1):129-35.

40.   Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis and rheumatism. 2003;48(12):3522-31.

41.   Gonzalez-Gay MA, Garcia-Porrua C, Gonzalez-Juanatey C, Miranda-Filloy JA, Blanco R, Llorca J. Biopsy-proven giant cell arteritis patients with coronary artery disease have increased risk of aortic aneurysmal disease and arterial thrombosis. Clinical and experimental rheumatology. 2013;31(1 Suppl 75):S94.

42.   Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(41):2873-926.

43.   Bienvenu B, Ly KH, Lambert M, Agard C, Andre M, Benhamou Y, et al. Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). La Revue de medecine interne. 2016;37(3):154-65.

44.   Mackie SL, Hensor EM, Morgan AW, Pease CT. Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis. Annals of the rheumatic diseases. 2014;73(1):143-8.

45.   Hachulla E, Boivin V, Pasturel-Michon U, Fauchais AL, Bouroz-Joly J, Perez-Cousin M, et al. Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis. Clin Exp Rheumatol. 2001;19(2):171-6.

46.   Alba MA, Garcia-Martinez A, Prieto-Gonzalez S, Tavera-Bahillo I, Corbera-Bellalta M, Planas-Rigol E, et al. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore). 2014;93(5):194-201.

47.   Nesher G, Nesher R, Mates M, Sonnenblick M, Breuer GS. Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S30-4.

48.   Muratore F, Kermani TA, Crowson CS, Green AB, Salvarani C, Matteson EL, et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford, England). 2015;54(3):463-70.

49.   Strehl C, Bijlsma JW, de Wit M, Boers M, Caeyers N, Cutolo M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016;75(6):952-7.

50.   Tuberculosis. In: NICE, editor.: NG33; 2016.

51.   Duru N, van der Goes MC, Jacobs JW, Andrews T, Boers M, Buttgereit F, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013;72(12):1905-13.

52.   Scarpignato C, Gatta L, Zullo A, Blandizzi C, Group S-A-F, Italian Society of Pharmacology tIAoHG, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179.

53.   Contraindications and special considerations. 2017 26/10/2017. In: Immunisation against infectious disease [Internet]. Public Health England; [5]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf.

54.   Rausch Osthoff AK, Niedermann K, Braun J, Adams J, Brodin N, Dagfinrud H, et al. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Annals of the rheumatic diseases. 2018;77(9):1251-60.

55.   Oliveira DS, Shinjo SK, Silva MG, de Sa-Pinto AL, Lima FR, Roschel H, et al. Exercise in Takayasu Arteritis: Effects on Inflammatory and Angiogenic Factors and Disease-Related Symptoms. Arthritis care & research. 2017;69(6):892-902.

56.   Aschwanden M, Daikeler T, Kesten F, Baldi T, Benz D, Tyndall A, et al. Temporal artery compression sign--a novel ultrasound finding for the diagnosis of giant cell arteritis. Ultraschall in der Medizin (Stuttgart, Germany : 1980). 2013;34(1):47-50.

57.   Diamantopoulos AP, Haugeberg G, Hetland H, Soldal DM, Bie R, Myklebust G. Diagnostic value of color Doppler ultrasonography of temporal arteries and large vessels in giant cell arteritis: a consecutive case series. Arthritis care & research. 2014;66(1):113-9.

58.   Habib HM, Essa AA, Hassan AA. Color duplex ultrasonography of temporal arteries: role in diagnosis and follow-up of suspected cases of temporal arteritis. Clinical rheumatology. 2012;31(2):231-7.

59.   Karahaliou M, Vaiopoulos G, Papaspyrou S, Kanakis MA, Revenas K, Sfikakis PP. Colour duplex sonography of temporal arteries before decision for biopsy: a prospective study in 55 patients with suspected giant cell arteritis. Arthritis research & therapy. 2006;8(4):R116.

60.   Nesher G, Shemesh D, Mates M, Sonnenblick M, Abramowitz HB. The predictive value of the halo sign in color Doppler ultrasonography of the temporal arteries for diagnosing giant cell arteritis. The Journal of rheumatology. 2002;29(6):1224-6.

61.   Reinhard M, Schmidt D, Hetzel A. Color-coded sonography in suspected temporal arteritis-experiences after 83 cases. Rheumatology international. 2004;24(6):340-6.

62.   Schmidt WA, Kraft HE, Vorpahl K, Volker L, Gromnica-Ihle EJ. Color duplex ultrasonography in the diagnosis of temporal arteritis. The New England journal of medicine. 1997;337(19):1336-42.

63.   LeSar CJ, Meier GH, DeMasi RJ, Sood J, Nelms CR, Carter KA, et al. The utility of color duplex ultrasonography in the diagnosis of temporal arteritis. Journal of vascular surgery. 2002;36(6):1154-60.

64.   Murgatroyd H, Nimmo M, Evans A, MacEwen C. The use of ultrasound as an aid in the diagnosis of giant cell arteritis: a pilot study comparing histological features with ultrasound findings. Eye (London, England). 2003;17(3):415-9.

65.   Aschwanden M, Imfeld S, Staub D, Baldi T, Walker UA, Berger CT, et al. The ultrasound compression sign to diagnose temporal giant cell arteritis shows an excellent interobserver agreement. Clinical and experimental rheumatology. 2015;33(2 Suppl 89):S-113-5.

66.   Pfadenhauer K, Weber H. Duplex sonography of the temporal and occipital artery in the diagnosis of temporal arteritis. A prospective study. The Journal of rheumatology. 2003;30(10):2177-81.

67.   Romera-Villegas A, Vila-Coll R, Poca-Dias V, Cairols-Castellote MA. The role of color duplex sonography in the diagnosis of giant cell arteritis. Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine. 2004;23(11):1493-8.

68.   Lie JT. Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis. Arthritis and rheumatism. 1990;33(8):1074-87.

69.   Schmidt WA, Seifert A, Gromnica-Ihle E, Krause A, Natusch A. Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology (Oxford, England). 2008;47(1):96-101.

70.   Bley TA, Uhl M, Carew J, Markl M, Schmidt D, Peter HH, et al. Diagnostic value of high-resolution MR imaging in giant cell arteritis. AJNR American journal of neuroradiology. 2007;28(9):1722-7.

71.   Bley TA, Weiben O, Uhl M, Vaith P, Schmidt D, Warnatz K, et al. Assessment of the cranial involvement pattern of giant cell arteritis with 3T magnetic resonance imaging. Arthritis and rheumatism. 2005;52(8):2470-7.

72.   Geiger J, Bley T, Uhl M, Frydrychowicz A, Langer M, Markl M. Diagnostic value of T2-weighted imaging for the detection of superficial cranial artery inflammation in giant cell arteritis. Journal of magnetic resonance imaging : JMRI. 2010;31(2):470-4.

73.   Klink T, Geiger J, Both M, Ness T, Heinzelmann S, Reinhard M, et al. Giant cell arteritis: diagnostic accuracy of MR imaging of superficial cranial arteries in initial diagnosis-results from a multicenter trial. Radiology. 2014;273(3):844-52.

74.   Siemonsen S, Brekenfeld C, Holst B, Kaufmann-Buehler AK, Fiehler J, Bley TA. 3T MRI reveals extra- and intracranial involvement in giant cell arteritis. AJNR American journal of neuroradiology. 2015;36(1):91-7.

75.   Rheaume M, Rebello R, Pagnoux C, Carette S, Clements-Baker M, Cohen-Hallaleh V, et al. High-Resolution Magnetic Resonance Imaging of Scalp Arteries for the Diagnosis of Giant Cell Arteritis: Results of a Prospective Cohort Study. Arthritis & rheumatology (Hoboken, NJ). 2017;69(1):161-8.

76.   Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Annals of the rheumatic diseases. 2018;77(5):636-43.

77.   Chrysidis S, Duftner C, Dejaco C, Schafer VS, Ramiro S, Carrara G, et al. Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group. RMD open. 2018;4(1):e000598.

78.   Jakobsson K, Jacobsson L, Mohammad AJ, Nilsson JA, Warrington K, Matteson EL, et al. The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis. BMC musculoskeletal disorders. 2016;17(1):363.

79.   Lariviere D, Benali K, Coustet B, Pasi N, Hyafil F, Klein I, et al. Positron emission tomography and computed tomography angiography for the diagnosis of giant cell arteritis: A real-life prospective study. Medicine. 2016;95(30):e4146.

80.   Blockmans D, Stroobants S, Maes A, Mortelmans L. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med. 2000;108(3):246-9.

81.   Prieto-Gonzalez S, Arguis P, Garcia-Martinez A, Espigol-Frigole G, Tavera-Bahillo I, Butjosa M, et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Annals of the rheumatic diseases. 2012;71(7):1170-6.

82.   Yamada I, Nakagawa T, Himeno Y, Numano F, Shibuya H. Takayasu arteritis: evaluation of the thoracic aorta with CT angiography. Radiology. 1998;209(1):103-9.

83.   Adler S, Sprecher M, Wermelinger F, Klink T, Bonel H, Villiger PM. Diagnostic value of contrast-enhanced magnetic resonance angiography in large-vessel vasculitis. Swiss medical weekly. 2017;147:w14397.

84.   Vaidyanathan S, Chattopadhyay A, Mackie SL, Scarsbrook AF. Comparative effectiveness of (18)F-FDG PET-CT and contrast-enhanced CT in the diagnosis of suspected large-vessel vasculitis. Br J Radiol. 2018:20180247.

85.   Muto G, Yamashita H, Takahashi Y, Miyata Y, Morooka M, Minamimoto R, et al. Large vessel vasculitis in elderly patients: early diagnosis and steroid-response evaluation with FDG-PET/CT and contrast-enhanced CT. Rheumatology international. 2014;34(11):1545-54.

86.   Chevalet P, Barrier JH, Pottier P, Magadur-Joly G, Pottier MA, Hamidou M, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol. 2000;27(6):1484-91.

87.   Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46(5):1309-18.

88.   Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2016;387(10031):1921-7.

89.   Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54(10):3310-8.

90.   Ntatsaki E, Carruthers D, Chakravarty K, D'Cruz D, Harper L, Jayne D, et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford). 2014;53(12):2306-9.

91.   Strehl C, Buttgereit F. Optimized glucocorticoid therapy: teaching old drugs new tricks. Mol Cell Endocrinol. 2013;380(1-2):32-40.

92.   Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol. 2008;4(10):525-33.

93.   Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis. 1989;48(8):658-61.

94.   Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of Tocilizumab in Giant-Cell Arteritis. The New England journal of medicine. 2017;377(4):317-28.

95.   Hunder GG, Sheps SG, Allen GL, Joyce JW. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med. 1975;82(5):613-8.

96.   Fehm HL, Benkowitsch R, Kern W, Fehm-Wolfsdorf G, Pauschinger P, Born J. Influences of corticosteroids, dexamethasone and hydrocortisone on sleep in humans. Neuropsychobiology. 1986;16(4):198-204.

97.   Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420-6.

98.   Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134(2):106-14.

99.   Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19(5):495-501.

100.   Mahr AD, Jover JA, Spiera RF, Hernandez-Garcia C, Fernandez-Gutierrez B, Lavalley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis and rheumatism. 2007;56(8):2789-97.

101.   De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis. 1986;45(2):136-8.

102.   Liozon F, Vidal E, Barrier J. Does dapsone have a role in the treatment of temporal arteritis with regard to efficacy and toxicity? Clin Exp Rheumatol. 1993;11(6):694-5.

103.   Schaufelberger C, Andersson R, Nordborg E. No additive effect of cyclosporin A compared with glucocorticoid treatment alone in giant cell arteritis: results of an open, controlled, randomized study. Br J Rheumatol. 1998;37(4):464-5.

104.   Schaufelberger C, Mollby H, Uddhammar A, Bratt J, Nordborg E. No additional steroid-sparing effect of cyclosporine A in giant cell arteritis. Scand J Rheumatol. 2006;35(4):327-9.

105. Adizie T, Christidis D, Dharmapaliah C, Borg F, Dasgupta B. Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series. Int J Clin Pract. 2012;66(9):906-9.

106. Diamantopoulos AP, Hetland H, Myklebust G. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. BioMed research international. 2013;2013:120638.

107. Hocevar A, Jese R, Rotar Z, Tomsic M. Does leflunomide have a role in giant cell arteritis? An open-label study. Clinical rheumatology. 2018.

108. Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, et al. A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. Arthritis & rheumatology (Hoboken, NJ). 2017;69(4):837-45.

109. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146(9):621-30.

110. Seror R, Baron G, Hachulla E, Debandt M, Larroche C, Puechal X, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis. 2014;73(12):2074-81.

111. Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L, Lopez-Longo J, Figueroa M, Belzunegui J, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Annals of the rheumatic diseases. 2008;67(5):625-30.

112. Mollan SP, Sharrack N, Burdon MA, Denniston AK. Aspirin as adjunctive treatment for giant cell arteritis. Cochrane Database Syst Rev. 2014(8):CD010453.

113. Tocilizumab for treating giant cell arteritis. In: NICE, editor.: TA518; 2018.

114. Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford, England). 2010;49(8):1594-7.

115. Coath F, Gillbert K, Griffiths B, Hall F, Kay L, Lanyon P, et al. Giant cell arteritis: new concepts, treatments and the unmet need that remains. Rheumatology (Oxford, England). 2018.

1
2
3
4
5
6
7
8
9
10
11

British Society for Rheumatology Audit Tool for Giant Cell Arteritis

Aim: This audit tool has been designed to help clinicians audit the investigation and management of giant cell arteritis (GCA) according to the 2019 BSR guidelines. It should be performed on an unbiased (e.g. consecutive) sample of patients presenting to a clinic or service.

Quality standards

- Following first medical contact in which GCA is suspected, patients should be reviewed by an appropriate specialist within 3 working days.

- Patients in whom GCA is strongly suspected should be treated with high-dose glucocorticoids on the same calendar day (either at least 40mg prednisolone equivalent, or intravenous methylprednisolone).

- Before or immediately after commencing high-dose glucocorticoids for suspected GCA, patients should have had blood sent to the laboratory for full blood count, CRP, and ESR (or plasma viscosity if ESR unavailable).

- Patients commenced on high-dose glucocorticoids for suspected GCA should undergo an additional confirmatory test, such as temporal artery biopsy or vascular imaging (e.g. vascular ultrasound, 3T MRI of cranial artery, or CT/PET).

- Patients with GCA-related visual symptoms (transient/permanent visual loss or diplopia) should be reviewed on the same calendar day by an ophthalmologist.

- Patients commencing high-dose glucocorticoids should have a random venous blood glucose or HbA1c or capillary blood glucose (CBG) checked within the first 2 weeks and any hyperglycaemia be managed appropriately.

- Patients commencing high-dose glucocorticoids for suspected GCA should have consideration of appropriate bone protection according to the applicable local or national guidelines (e.g. calcium and vitamin D, with oral bisphosphonate unless contra-indicated).

- Patients with confirmed GCA should be offered written information about their condition (for example, the Versus Arthritis leaflet on GCA, or locally-agreed equivalent), including advice on sources of further information and support in addition to medical advice from their care providers. Patients should be advised which matters could be dealt with by their GP, and how to contact their specialist if they need to.

- Patients with confirmed GCA should have documentation of a discussion about what symptoms may signal GCA relapse, and what action they should take in the event of a possible relapse, including the appropriate level of urgency for symptoms that may indicate threatened visual loss.

For patients with suspected GCA:

1. What was the interval in working days between initial medical contact and specialist review?

0 - 1 ☐   2-3 ☐   4-5 ☐   >5 ☐

2. What was the interval between first strong suspicion of GCA and first initiation of high-dose glucocorticoid therapy?

<24 hrs ☐   24-48 hours ☐   >48 hours ☐   not strong suspicion ☐

3. Were FBC, CRP and either ESR or plasma viscosity requested in the 3 weeks prior to, or immediately after initiation of high-dose glucocorticoid therapy?

yes ☐   no ☐

4. What was the initial daily dose of prednis(ol)one therapy for GCA?

<40mg ☐   40-60mg ☐   >60mg ☐   iv therapy ☐   never treated ☐

5. What additional confirmatory test was performed?

ultrasound   ☐   biopsy   ☐   other appropriate imaging test   ☐   no test ☐

6. If visual symptoms were documented, did the patient undergo urgent ophthalmology review?

Yes   ☐   No   ☐

Ophthalmological diagnosis was (Please circle) Anterior ischaemic optic neuropathy, double vision, central retinal artery occlusion, branch retinal artery occlusion, choroidal ischaemia, other

Additional items, for patients with confirmed GCA:

7. Within the first 2 weeks of treatment which of these are documented?

random glucose or HbA1c ☐   blood pressure ☐

vitamin D and calcium prescribed ☐   appropriate bone protection therapy ☐

8. Is there documentation of provision of written information about the condition, including information about sources of further information and support?

Yes ☐   No ☐

9. Is there documentation of a discussion with the patient/carers about symptoms to watch out for and what to do if they experience symptoms suggesting GCA relapse?

Yes ☐   No ☐

1
2
3
4
5
6
7
8
9
10

Name:	Email address:

11
12 Sarah Mackie   s.l.mackie@leeds.ac.uk
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34 Asad Khan   asad.khan@heartofengland.nhs.uk
35
36
37
38
39
40
41 Christian Dejaco   christian.dejaco@gmx.net
42
43
44
45
46 Lorna Murray Neill   gdneill@gotadsl.co.uk
47
48 Peter A. Merkel   pmerkel@upenn.edu
49
50
51 Maria C Cid   mccid@clinic.cat
52
53
54
55
56
57
58 Kate   Gilbert

60

1
2   Dorothy Byrne   dbyrne@channel4.co.uk
3
4   Elisabeth Brouwer   e.brouwer@umcg.nl
5
6
7
8
9   Dr. Elaine A. Yacyshyn eyacyshyn@ualberta.ca
10
11
12
13
14   Wolfgang Andreas   schmidt.wa@t-online.de
     Schmidt
15
16
17   Eric L Matteson   matteson.eric@mayo.edu
18
19   Justin Mason   justin.mason@imperial.ac.uk
20
21
22
23
24   Susan P Mollan   soozmollan@doctors.org.uk
25
26
27
28
29
30
31
32   Lorna Neill   gdneill@gotadsl.co.uk
33
34   Bhaskar Dasgupta   bhaskar.dasgupta@southend.nhs.uk
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52   Peter Lanyon   peter.lanyon@nottingham.ac.uk

59
60

Professional role/occupation:	Role on this Guideline:	Do you have, or have you had, any direct financial interests related to this Guideline's known or likely content in the last year?*
Rheumatologist	Rheumatologist - topic specialist	No
Consultant rheumatologist	Rheumatologist - topic specialist	Yes
Rheumatologist, Associate Professor	Rheumatologist - topic specialist	Yes
retired	Patient representative	No
Professor of Medicine and Epidemiology	Rheumatologist - topic specialist	Yes
Senior Consultant. Hospital Clinic Barcelona. Associate professor University of Barcelona. senior group leader. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)	Other medical specialist background	Yes
kate.gilbert@pmrgca.org.uk	Patient representative	No

Head of News and Current Affairs Channel 4	Patient representative	No
Rheumatologist	Rheumatologist - topic specialist	No
Rheumatologist	Rheumatologist - topic specialist	No
Physician	Rheumatologist - topic specialist	Yes
Rheumatologist	Rheumatologist - topic specialist	No
Professor of Rheumatology	Rheumatologist - topic specialist	Yes
Neuro-Ophthalmologist	Other medical specialist background	Yes
Retired	Patient representative	No
Consultant Rheumatologist	Rheumatologist - topic specialist	Yes
Consultant Rheumatologist	Rheumatologist - topic specialist	No

Description of your direct financial Interest(s):	Do you have, or have you had, any direct non-financial professional and personal interests related to this Guideline's known or likely content in the last year?*
	Yes
Speaker's fees of £750 agreed with Chugai for event dated 27th June 2019 - "Spotlight on Giant Cell Arteritis".	Yes
consultancy fees and honoraries from Roche, Sanofi, AbbVie, MSD, Pfizer, UCB, BMS	Yes
N/A	Yes
Consulting: AbbVie, AstraZeneca, Biogen, Boeringher-	Yes
In the last year I received a research grant from Kiniksa and consulting fees from Abbvie and Janssen.	Yes
	Yes

1		
2		Yes
3		
4		Yes
5		
6		
7		
8		
9		Yes
10		
11		
12		
13		
14	Consulting fees: GlaxoSmithKline,	Yes
15		
16		
17		Yes
18		
19	I have received	Yes
20	speaker fees and	
21	consultancy fees from	
22	Roche/Chugai	
23	Roche (Advisory	
24	boards 2016, 2017)	Yes
25	Roche speaker fees	
26	(2016, 2017, 2018,	
27	2019) Chugai-Roche	
28	Ltd speaker fees	
29	(2018, 2019)	
30		
31		
32		
33		Yes
34	Paid consultancies for	
35	membership of	Yes
36	Clinical Trials Advisory	
37	Boards, for	
38	developing trials	
39	protocols as well as	
40	speaker fees from	
41	Roche-Chugai, Sanofi,	
42	ERT, BMS, GSK,Abbvie	
43	as well as Ultrasound	
44	workshop/GCA	
45	symposium grants to	
46	Southend university	
47	Hospital	
48		
49		
50		
51		
52		
		Yes
59		
60		

Description of your direct non-financial Interest(s):	Do you have, or have you had, any indirect interests related to this	
I am Patron of PMRGCAuk which is a patient support group (not to my knowledge in receipt of funding from industry) that also undertakes advocacy. I am employed by the University of Leeds as an academic rheumatologist and as required for my role I have published various academic publications on GCA. I am also a founder member of the TARGET Research Consortium https://lida.leeds.ac.uk/target-2/about-us/ which is a partnership between academics, industry and clinicians. I am co-chair of the OMERACT PMR Working Group and a member of the OMERACT Vasculitis Working Group which includes large vessel vasculitis as part of its remit. I am also encouraged to carry out public engagement roles and I speak sometimes to patient support groups. I was interviewed by a journalist on behalf of a US patient support group called creakyjoints.org and was quoted in the online article but I avoided being quoted on any specific therapy https://creakyjoints.org/education/giant-cell-arteritis/ I was sub-investigator at my hospital for the licensing RCT of tocilizumab for giant cell arteritis (GiACTA), site PI and for sirukumab for giant cell arteritis (SIRRESTA) I am local principal investigator and UK CI (for purposes of IRAS) for an international multicentre industry sponsored trial of sarilumab for GCA.	Yes	
I have co-authored a review entitled "Imaging in Giant Cell Arteritis" (DOI 10.1007/s11926-015-0527-y). This review is related to the likely contents of the guideline but did not form part of the evidence base for it.	No	
First author of EULAR imaging recommendations in large vessel vasculitils First author of ACR/EULAR recommendations for management of PMR Coauthor of management recommendations for Large vessel vasculitis	No	
Current Chair of PMR-GCA Scotland	No	
Research Support: Bristol-Myers Squibb, Genentech/Roche	No	
In the last year I have participated in clinical trials sponsored by GSK, and Kiniksa I have participated as co-author in publications of work sponsored by Roche	No	
I am a representative of PMRGCAuk, the national charity for patients with polymyalgia rheumatica and giant cell arteritis, and my involvement with this guideline enhances the public profile of the charity.	No	

Vice Chair of PMRGCAuk	No	
Presently I perform cohort research in GCA as an employee of the UMCG in the Netherlands. Part of the work is funded by Reuma Nederland. I also lead/ am involved in the development of the local and national guidelines for GCA in the Netherlands.	Yes	
Associate Professor Rheumatology at University of Alberta i) I have been asked to speak at an educational event sponsored by a pharmaceutical company which is related to my area of expertise. Action: Wrote my own slides, did not accept financial payment which went to Institution	No	
Participation in trials / studies: GlaxoSmithKline, Novartis, Roche, Sanofi	No	
Task force participation: EULAR 2018 standardized core set of data to be collected in giant cell arteritis registries and databases	No	
I am Professor of Rheumatology at Imperial College London and Head of the Cardiovascular Division	No	
I was the representative from the Royal College of Ophthalmologists for this guideline. I was part of the EULAR GCA guideline group. I am part of the European Headache Federation GCA guideline group. I was author of the Cochrane review in recommending utility of Aspirin in GCA.	No	
Chair of PMR-GCA Scotland Patient representative on EULAR working group on Imaging in LVV	No	
I am the Honorary President of PMRGCAuk , a patient support charity I was investigator for GiACTA, co-author of the NEJM article that led to approval of tocilizumab for GCA, and led the BSR response to NICE that facilitated NICE approval of tocilizumab for relapsing/refractory GCA I was the subject of the BBC2 Health program 'Trust me, I'm a doctor' made on GCA and released Feb 2017 I have authored over 200 artcles on GCA,PMR and was the first author of the original BSR guidance on GCA as well PMR (including the EULAR ACR guidance on PMR)	No	
I was President of the BSR April 2016-18. I currently chair the Rare Autoimmune Rheumatic Disease Alliance.	No	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
54
55
56
57
58
59
60

Description of your indirect Interest(s):

I have not received direct financial remuneration

from any pharmaceutical company in the past year. I was however sponsored to attend EULAR by Roche in 2019 (hotel flights and registration only). Prior to the last year, I have served on medical advisory boards

for Roche and Sanofi but since 2015 the payments for these have all gone to my employer, not to me personally. The unit where I work has received funding from multiple pharmaceutical companies. Specifically the University of Leeds has been funded

by Roche to run a post-marketing surveillance registry of patients with giant cell arteritis in regard to tocilizumab: GCAT. https://lida.leeds.ac.uk/target-2/active-research-projects/gcatregistry/.   I am currently serving as associate editor for the journal

Rheumatology (Oxford).

N/A